US20060216286A1 - Novel screening method - Google Patents

Novel screening method Download PDF

Info

Publication number
US20060216286A1
US20060216286A1 US10/552,014 US55201405A US2006216286A1 US 20060216286 A1 US20060216286 A1 US 20060216286A1 US 55201405 A US55201405 A US 55201405A US 2006216286 A1 US2006216286 A1 US 2006216286A1
Authority
US
United States
Prior art keywords
amino acid
acid sequence
protein
same
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/552,014
Other languages
English (en)
Inventor
Yasuaki Ito
Ryo Fujii
Makoto Kobayashi
Shuji Hinuma
Tadatoshi Hashimoto
Yasuhiro Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUJII, RYO, HINUMA, SHUJI, ITO, YASUAKI, TANAKA, YASUHIRO, HASHIMOTO, TADATOSHI, KOBAYASHI, MAKOTO
Publication of US20060216286A1 publication Critical patent/US20060216286A1/en
Priority to US12/428,877 priority Critical patent/US7972800B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention relates to use of a G protein-coupled receptor protein (GPR39).
  • GPR39 G protein-coupled receptor protein
  • G protein-coupled receptor proteins GPCR
  • TMR seven-transmembrane receptor proteins
  • G protein-coupled receptor proteins are present on the cell surface of each functional cell and organ in the body, and play a vitally important physiological role as the target of the molecules that regulate the functions of the cells and organs, e.g., physiologically active substances such as peptide hormones, nucleic acids, amines, lipids, etc.
  • Receptor proteins transmit signals into cells via binding with physiologically active substances, and the signals induce various reactions such as activation and inhibition of the cells.
  • G protein-coupled receptor proteins will elucidate the functional mechanisms in various cells and organs in the body to provide a very important means for development of drugs closely associated with these functions.
  • physiologically active substances are found in numerous sites of the body and regulate the physiological functions through their corresponding receptor proteins.
  • Many unknown hormones, neurotransmitters or other physiologically active substances still exist in the body and, as to their receptor proteins, many of these proteins have not yet been reported.
  • a lot remains yet to be established if there are subtypes of known receptor proteins or if there are differences depending on species.
  • G protein-coupled receptor proteins are useful in search for a novel physiological active substance (i.e., ligand) using the signal transduction activity as an indicator and in search for agonists and antagonists to the receptor protein.
  • a novel physiological active substance i.e., ligand
  • agonists and antagonists to the receptor protein may be prepared by analyzing the physiological action of the receptor protein through inactivation experiment of the receptor protein (knockout animal).
  • Ligands, agonists or antagonists, etc. of these receptor proteins are expected to be utilized as preventive/therapeutic agents or diagnostic agents for diseases associated with dysfunction or hyperfunction of the G protein-coupled receptor proteins.
  • the G protein coupled receptor proteins may be used not only for administration of antagonists or agonists for the receptor proteins, but also for gene therapy by introducing the receptor protein gene into the body (or some particular organs) or by introducing the antisense nucleic acid of the receptor protein gene.
  • information on the base sequence of the receptor protein is essentially required for investigating deletion or mutation on the gene.
  • the receptor protein gene is also applicable as preventive/therapeutic agents or diagnostic agents for diseases associated with dysfunction of the receptor protein.
  • the present invention relates to determination of ligands for orphan G protein-coupled receptor proteins with unknown functions and use of the G protein-coupled receptor proteins and their ligands. That is, the present invention aims at providing a method of screening a compound (an antagonist or agonist) or its salt that changes the binding property of the ligand to the G protein-coupled receptor protein; a kit for the screening; a compound (an antagonist or agonist) or its salt that changes the binding property of the ligand to the G protein-coupled receptor protein, which is obtainable by using the screening method or the screening kit; a pharmaceutical comprising a compound (an antagonist or agonist) or its salt that changes the binding property of the ligand to the G protein-coupled receptor protein or a compound that changes the expression level of the G protein-coupled receptor protein; and so on.
  • ligands for human-derived GPR39 are particular metal elements or salts thereof. Based on these findings, the inventors have continued further investigations and come to accomplish the present invention.
  • the present invention provides the following features.
  • G protein-coupled receptor protein is a G protein-coupled receptor protein consisting of the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 6 or SEQ ID NO: 8.
  • a kit for screening a compound or element or a salt thereof that changes the binding property or signal transduction of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, to an ionizable metal element or a salt thereof, which comprises (1) said receptor protein, its partial peptide, or a salt thereof and (2) said metal element or a salt thereof.
  • a compound or element or a salt thereof that changes the binding property or signal transduction of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, to an ionizable metal element or a salt thereof, which is obtainable by using the screening method according to [1] or the screening kit according to [3].
  • a pharmaceutical which comprises a compound or element or a salt thereof that changes the binding property or signal transduction of an ionizable metal element or a salt thereof to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof.
  • cytokines e.g., IL-8
  • a prophylactic/therapeutic agent for renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease which comprises an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof.
  • cytokines
  • a method of screening an agonist for a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises assaying an intracellular Ca 2+ level increasing activity when a test compound or element or a salt thereof is brought in contact with a cell containing said receptor protein.
  • a method of screening an agonist for or an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using (1) said receptor protein or its partial peptide, or a salt thereof and (2) a compound or element or a salt thereof that changes the binding property of said receptor protein or a salt thereof to an ionizable metal element or a salt thereof.
  • a kit for screening an agonist for or an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises (1) said receptor protein or its partial peptide, or a salt thereof and (2) a compound or element or a salt thereof that changes the binding property of said receptor protein or a salt thereof to an ionizable metal element or a salt thereof.
  • An agonist for or an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which is obtainable by using the screening method according to [11] or the screening kit according to [12].
  • a pharmaceutical comprising an agonist for or an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof.
  • cytokines e.g., IL-8
  • a prophylactic/therapeutic agent for renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease which comprises an antibody to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, or a salt thereof.
  • a diagnostic agent for overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria, prostatic hyperplasia-induced pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms or various disorders caused by urinary calculus or inflammatory diseases e.g., diabetic complications such as neuropathy, macroangiopathy, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases (e.g., asthma, atopic dermatitis or chronic obstructive pulmonary disease (COPD)), which comprises an antibody to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, or a salt thereof.
  • inflammatory diseases e.g., diabetic complications such as neuropathy, macroangiopathy, etc.; inflammatory bowel diseases such as ulcerative colitis
  • a prophylactic/therapeutic agent for renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease which comprises a polynucleotide containing the entire or part of a base sequence complementary to a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide.
  • a method of screening a compound or its salt that changes the expression level of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 to prevent/treat growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression or menoxenia, renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease, which comprises using a polynucleotide comprising a polynucleotide encoding said receptor protein or its partial peptide.
  • a kit for screening a compound or its salt that changes the expression level of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 to prevent/treat growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression or menoxenia, renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease, which comprises a polynucleotide comprising a polynucleotide encoding said receptor protein or its partial peptide.
  • a kit for screening a compound or a salt thereof that changes the expression level of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, to prevent/treat hypotonic bladder induced by sensory decrease of the bladder, hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria, prostatic hyperplasia-induced pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms or various disorders caused by urinary calculus, a drug to regulate the secretion of cytokines (e.g., IL-8), or a drug to prevent/treat inflammatory diseases (e.g., diabetic complications such as neuropathy, macroangiopathy, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases
  • a compound or its salt that changes the expression level of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide to prevent/treat growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression or menoxenia, renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease, which is obtainable by using the screening method according to [27] or the screening kit according to [29].
  • a compound or a salt thereof that changes the expression level of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, to prevent/treat hypotonic bladder induced by sensory decrease of the bladder, hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria, prostatic hyperplasia-induced pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms or various disorders caused by urinary calculus, a drug to regulate the secretion of cytokines (e.g., IL-8), or a compound or a salt thereof to prevent/treat inflammatory diseases (e.g., diabetic complications such as neuropathy, macroangiopathy, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome;
  • cytokines e.g., IL-8
  • a prophylactic/therapeutic agent for renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease which comprises a compound or its salt that decreases the expression level of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide.
  • a method of preventing/treating renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease which comprises administering to a mammal an effective dose of (i) an antibody to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof, (ii) a polynucleotide comprising the entire or part of a base sequence complementary to a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, (iii) an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, or (iv) a compound or its salt that decreases the expression level of a G
  • a method of preventing/treating overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria, prostatic hyperplasia-induced pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms or various disorders caused by urinary calculus a method of suppressing the expression of cytokines (e.g., IL-8), or a method of preventing/treating inflammatory diseases (e.g., diabetic complications such as neuropathy, macroangiopathy, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases (e.g., asthma, atopic dermatitis or chronic obstructive pulmonary disease (COPD)), which comprises administering to a mammal an effective dose of (i) an antibody to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID
  • a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof
  • a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide
  • an agonist for a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof
  • a compound or its salt that increases the expression level of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, to manufacture a prophylactic/therapeutic agent for growth retardation, wounds, burn, cold constitution, declining of learning ability, hypo
  • a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof
  • a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide
  • an agonist for a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof
  • a compound or its salt that increases the expression level of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, to manufacture a prophylactic/therapeutic agent for hypotonic bladder induced by sensory decrease of the bladder or hypotonic bladder
  • the present invention further provides the following features and so on.
  • the cell stimulating activity mediated by GPR39 is assayed (i) when a compound or element or a salt thereof that activates GPR39 is brought in contact with GPR39 expressed on the cell membrane of a transformant by culturing the transformant transformed with a recombinant vector bearing a DNA comprising a DNA encoding GPR39 and (ii) when a compound or element or a salt thereof that activates GPR39 and a test compound or element or a salt thereof are brought in contact with GPR39 expressed on the cell membrane of a transformant by culturing the transformant transformed with a recombinant vector bearing a DNA comprising a DNA encoding GPR39, followed by comparison of (i) and (ii).
  • a method for confirming that a drug for preventing/treating growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression or menoxenia is an agonist for a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using said receptor protein or a salt thereof.
  • a method for confirming that a drug for preventing/treating hypotonic bladder induced by sensory decrease of the bladder or hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs or a drug for promoting the secretion of cytokines is an agonist for a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using said receptor protein or a salt thereof.
  • a method for confirming that a drug for preventing/treating renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease is an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using said receptor protein or a salt thereof.
  • FIG. 1 shows the results obtained by monitoring changes in intracellular calcium levels when cadmium chloride was added to human GPR39-GFP expression vector-transfected CHO cell line (CHO/hGPR39-GFP).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels.
  • Symbol ⁇ (open square) designates the case where 300 ⁇ M of cadmium chloride was added
  • symbol (open triangle) designates the case where 100 ⁇ M of cadmium chloride was added
  • symbol ⁇ designates the case where 10 ⁇ M of cadmium chloride was added.
  • FIG. 2 shows the results obtained by monitoring changes in intracellular calcium levels when zinc chloride was added to human GPR39-GFP expression vector-transfected CHO cell line (CHO/hGPR39-GFP).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels.
  • Symbol ⁇ (open square) designates the case where 300 ⁇ M of zinc chloride was added
  • symbol (open triangle) designates the case where 100 ⁇ M of zinc chloride was added
  • symbol ⁇ designates the case where 10 ⁇ M of zinc chloride was added.
  • FIG. 3 shows the results obtained by monitoring changes in intracellular calcium levels when copper chloride was added to human GPR39-GFP expression vector-transfected CHO cell line (CHO/hGPR39-GFP).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol ⁇ (open square) designates the case where 300 ⁇ M of copper chloride was added, symbol (open triangle) designates the case where 100 ⁇ M of copper chloride was added and symbol ⁇ (open circle) designates the case where 10 ⁇ M of copper chloride was added.
  • FIG. 4 shows the results obtained by monitoring changes in intracellular calcium levels when nickel chloride was added to human GPR39-GFP expression vector-transfected CHO cell line (CHO/hGPR39-GFP).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol ⁇ (open square) designates the case where 300 ⁇ M of nickel chloride was added, symbol (open triangle) designates the case where 100 ⁇ M of nickel chloride was added and symbol ⁇ (open circle) designates the case where 10 ⁇ M of nickel chloride was added.
  • FIG. 5 shows the expression distribution of GPR39 mRNA in human tissues. “Copies/25 ng total RNA” designates the number of copies per 25 ng of total RNA.
  • FIG. 6 shows the expression level of GPR39 mRNA in human primary culture cells. “Copies/25 ng total RNA” designates the number of copies per 25 ng of total RNA.
  • FIG. 7 shows the expression of GPR39 mRNA in human colon cancer cell line. “Copies/25 ng total RNA” designates the number of copies per 25 ng of total RNA.
  • FIG. 8 shows the results obtained by monitoring pH changes in extracellular fluids using a cytosensor, when nickel chloride was added to human GPR39 expression vector-transfected CHO cell line (CHO/hGPR39).
  • Cycles designates the number of detecting the rate of pH change after the addition.
  • Chicles designates the number of detecting the rate of pH change after the addition.
  • Chicles designates the number of detecting the rate of pH change after the addition.
  • “Change of Acidification Rate (%)” designates pH changes (acidification rate) in extracellular fluids and reflects the cell respiration rate.
  • Symbols ⁇ (closed diamond), ⁇ (closed triangle) and ⁇ (open square) designate GPR39-expressed cells, TGR7-expressed cells and mock cells, respectively.
  • FIG. 9 shows the results obtained by monitoring changes in intracellular calcium levels when cobalt chloride was added to rat GPR39 expression vector-transfected CHO cell line (CHO/rGPR39).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol (open diamond) designates the case where 3000 ⁇ M of cobalt chloride was added, symbol ⁇ (open square) designates the case where 1000 ⁇ M of cobalt chloride was added, and symbol (open triangle) designates the case where 300 ⁇ M of cobalt chloride was added.
  • FIG. 10 shows the results obtained by monitoring changes in intracellular calcium levels when nickel chloride was added to rat GPR39 expression vector-transfected CHO cell line (CHO/rGPR39).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol (open diamond) designates the case where 100 ⁇ M of nickel chloride was added, symbol ⁇ (open square) designates the case where 30 ⁇ M of nickel chloride was added, and symbol (open triangle) designates the case where 10 ⁇ M of nickel chloride was added.
  • FIG. 11 shows the results obtained by monitoring changes in intracellular calcium levels when copper chloride was added to rat GPR39 expression vector-transfected CHO cell line (CHO/rGPR39).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol (open diamond) designates the case where 100 ⁇ M of copper chloride was added, symbol ⁇ (open square) designates the case where 30 ⁇ M of copper chloride was added, and symbol (open triangle) designates the case where 10 ⁇ M of copper chloride was added.
  • FIG. 12 shows the results obtained by monitoring changes in intracellular calcium levels when zinc chloride was added to rat GPR39 expression vector-transfected CHO cell line (CHO/rGPR39).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol (open diamond) designates the case where 100 ⁇ M of zinc chloride was added, symbol ⁇ (open square) designates the case where 30 ⁇ M of zinc chloride was added, and symbol (open triangle) designates the case where 10 ⁇ M of zinc chloride was added.
  • FIG. 13 shows the results obtained by monitoring changes in intracellular calcium levels when cadmium chloride was added to rat GPR39 expression vector-transfected CHO cell line (CHO/rGPR39).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol (open diamond) designates the case where 3000 ⁇ M of cadmium chloride was added, symbol ⁇ (open square) designates the case where 1000 ⁇ M of cadmium chloride was added, and symbol (open triangle) designates the case where 300 ⁇ M of cadmium chloride was added.
  • FIG. 14 shows the results obtained by monitoring changes in intracellular calcium levels when nickel chloride was added to mouse GPR39 expression vector-transfected CHO cell line (CHO/mGPR39).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol (open diamond) designates the case where 300 ⁇ M of nickel chloride was added, symbol ⁇ (open square) designates the case where 100 ⁇ M of nickel chloride was added, and symbol (open triangle) designates the case where 30 ⁇ M of nickel chloride was added.
  • FIG. 15 shows the results obtained by monitoring changes in intracellular calcium levels when cobalt chloride was added to mouse GPR39 expression vector-transfected CHO cell line (CHO/mGPR39).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol (open diamond) designates the case where 3000 ⁇ M of cobalt chloride was added, symbol ⁇ (open square) designates the case where 1000 ⁇ M of cobalt chloride was added, and symbol (open triangle) designates the case where 300 ⁇ M of cobalt chloride was added.
  • FIG. 16 shows the results obtained by monitoring changes in intracellular calcium levels when copper chloride was added to mouse GPR39 expression vector-transfected CHO cell line (CHO/mGPR39).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol (open diamond) designates the case where 300 ⁇ M of copper chloride was added, symbol ⁇ (open square) designates the case where 100 ⁇ M of copper chloride was added, and symbol (open triangle) designates the case where 30 ⁇ M of copper chloride was added.
  • FIG. 17 shows the results obtained by monitoring changes in intracellular calcium levels when zinc chloride was added to mouse GPR39 expression vector-transfected CHO cell line (CHO/mGPR39).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol (open diamond) designates the case where 300 ⁇ M of zinc chloride was added, symbol ⁇ (open square) designates the case where 100 ⁇ M of zinc chloride was added, and symbol (open triangle) designates the case where 30 ⁇ M of zinc chloride was added.
  • FIG. 18 shows the results obtained by monitoring changes in intracellular calcium levels when cadmium chloride was added to mouse GPR39 expression vector-transfected CHO cell line (CHO/mGPR39).
  • “Time (sec)” designates a time period (second) after the addition.
  • “Counts” designates changes in intracellular calcium levels. Symbol (open diamond) designates the case where 3000 ⁇ M of cadmium chloride was added, symbol ⁇ (open square) designates the case where 1000 ⁇ M of cadmium chloride was added, and symbol (open triangle) designates the case where 300 ⁇ M of cadmium chloride was added.
  • FIG. 19 shows the tissue distribution of GPR39 mRNA in rats by RT-PCR. “Copies/25 ng total RNA” designates the number of copies per 25 ng of total RNA.
  • FIG. 20 shows the expression level of GPR39 mRNA in cell lines by RT-PCR.
  • Cell lines on the abscissa designates cell lines, and “human,” “mouse” and “rat” designate human, mouse and rat, respectively.
  • Copies/25 ng total RNA designates the number of copies per 25 ng of total RNA.
  • GPR39 used in the present invention is a receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1.
  • GPR39 may be any protein derived from, for example, any cell of human and mammal (e.g., guinea pig, rat, mouse, rabbit, swine, sheep, bovine, monkey, etc.); any cell (e.g., splenocyte, nerve cells, glial cells, ⁇ cells of pancreas, bone marrow cells, mesangial cells, Langerhans' cells, epidermic cells, epithelial cells, endothelial cells, fibroblasts, fibrocytes, myocytes, fat cells, immune cells (e.g., macrophage, T cells, B cells, natural killer cells, mast cells, neutrophils, basophils, eosinophils, monocytes), megakaryocytes, synovial cells, chondrocytes, bone cells, osteoblasts, osteoclasts, mammary gland cells, hepatocytes or interstitial cells; or the corresponding precursor cells, stem cells, cancer cells, etc.) or cells originated from
  • the amino acid sequence comprising substantially the same amino acid sequence as the amino acid sequence includes, for example, an amino acid sequence having at least about 80% homology, preferably at least about 90% homology and more preferably at least about 95% homology, to the amino acid sequence represented by SEQ ID NO: 1, and the like.
  • Examples of the protein of the present invention comprising substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 include a protein comprising substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 and preferably having the activity substantially equivalent to the protein consisting of the amino acid sequence represented by SEQ ID NO: 1, etc.
  • substantially equivalent activity examples include a ligand binding activity, a signal transduction activity, etc.
  • the term substantially equivalent is used to mean that the activities are the same in nature. Although it is preferred that activities such as the ligand binding and signal transduction activities, etc. be equivalent (e.g., about 0.01- to about 100-fold, preferably about 0.5- to about 20-fold, more preferably about 0.5- to about 2-fold), quantitative factors such as a level of these activities, a molecular weight of the protein, etc. may differ.
  • the activities such as ligand binding and signal transduction activities or the like can be determined according to publicly known methods, for example, by the ligand determination methods or the screening methods that will be later described.
  • proteins having the following amino acid sequences are used as GPR39: a) amino acid sequences wherein at least 1 or 2 amino acids (preferably approximately 1 to 30 amino acids, more preferably approximately 1 to 10 amino acids and most preferably several (1 to 5) amino acids) are deleted of the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 6 or SEQ ID NO: 8; b) amino acid sequences wherein at least 1 or 2 amino acids (preferably approximately 1 to 30 amino acids, more preferably approximately 1 to 10 amino acids and most preferably several (1 to 5) amino acids) are added to the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 6 or SEQ ID NO: 8; c) amino acid sequences wherein at least 1 or 2 amino acids (preferably approximately 1 to 30 amino acids, more preferably approximately 1 to 10 amino acids and most preferably several (1 to 5) amino acids) in the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 6, or SEQ ID NO: 8 are substituted by other amino acids; or d) combination of these amino acids
  • GPR39 is represented in accordance with the conventional way of describing peptides, that is, the N-terminus (amino terminus) at the left hand and the C-terminus (carboxyl terminus) at the right hand.
  • the C-terminus may be in any form of a carboxyl group (—COOH), carboxylate (—COO ⁇ ), an amide (—CONH 2 ) or an ester (—COOR).
  • ester group shown by R examples include a C 1-6 alkyl group such as methyl, ethyl, n-propyl, isopropyl, n-butyl, etc.; a C 3-8 cycloalkyl group such as cyclopentyl, cyclohexyl, etc.; a C 6-12 aryl group such as phenyl, ⁇ -naphthyl, etc.; a C 7-14 aralkyl group such as a phenyl-C 1-2 -alkyl group, e.g., benzyl, phenethyl, etc., or an ⁇ -naphthyl-C 1-2 -alkyl group such as ⁇ -naphthylmethyl, etc.; and the like.
  • pivaloyloxymethyl or the like which is used widely as an ester for oral administration, may also be used.
  • GPR39 contains a carboxyl group (or a carboxylate) at a position other than the C-terminus, it may be amidated or esterified and such an amide or ester is also included within GPR39.
  • the ester group may be the same group as that described with respect to the C-terminus described above.
  • examples of GPR39 include variants of the above proteins, wherein the amino group at the N-terminal methionine residue of the protein supra is protected with a protecting group (for example, a C 1-6 acyl group such as a C 2-6 alkanoyl group, e.g., formyl group, acetyl group, etc.); those wherein the N-terminal region is cleaved in vivo and the glutamyl group thus formed is pyroglutaminated; those wherein a substituent (e.g., —OH, —SH, amino group, imidazole group, indole group, guanidino group, etc.) on the side chain of an amino acid in the molecule is protected with a suitable protecting group (e.g., a C 1-6 acyl group such as a C 2-6 alkanoyl group, e.g., formyl group, acetyl group, etc.), or conjugated proteins such as glycoproteins bound to sugar
  • GPR39 examples include human-derived GPR39 consisting of the amino acid sequence represented by SEQ ID NO: 1, mouse-derived GPR39 consisting of the amino acid sequence represented by SEQ ID NO: 6, rat-derived GPR39 consisting of the amino acid sequence represented by SEQ ID NO: 8, etc.
  • Human-derived GPR39 is a publicly known protein described in Genomics, 1997 Dec. 15; 46(3): 426-34, WO2002/61087, US2002/004491, WO2002/39885, WO2002/71928, WO2001/81634, WO2002/79492 or WO2002/86443.
  • any partial peptide can be used so long as it can be a partial peptide of the aforesaid GPR39.
  • GPR39 protein molecules for example, those having a site exposed to the outside of a cell membrane and having substantially the same receptor binding activity can be used.
  • the partial peptide of GPR39 having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 6 or SEQ ID NO: 8 is a peptide containing the parts analyzed to be extracellular domains (hydrophilic domains) in the hydrophobic plotting analysis.
  • a peptide containing a hydrophobic domain in part can be used as well.
  • the peptide may contain each domain separately or plural domains together.
  • the amino acid sequence having substantially the same amino acid sequence includes an amino acid sequence having at least about 85% homology, preferably at least about 90% homology and more preferably at least about 95% homology, to these amino acid sequences.
  • Homology in the amino acid sequence can be measured under the same conditions using the homology scoring algorithm NCBI BLAST as described above.
  • substantially the same receptor activity has the same significance as described above.
  • the “substantially the same receptor activity” can be assayed by the same manner as described above.
  • the partial peptide of the present invention may contain amino acid sequences, of which at least 1 or 2 amino acids (preferably approximately 1 to 10 amino acids, more preferably several (1 to 5) amino acids) are deleted; to which at least 1 or 2 amino acids (preferably approximately 1 to 20 amino acids, more preferably approximately 1 to 10 amino acids, and most preferably several (1 to 5) amino acids) are added; or, in which at least 1 or 2 amino acids (preferably approximately 1 to 10 amino acids, more preferably several and most preferably approximately 1 to 5 amino acids) are substituted by other amino acids.
  • at least 1 or 2 amino acids preferably approximately 1 to 10 amino acids, more preferably several (1 to 5) amino acids
  • amino acids preferably approximately 1 to 20 amino acids, more preferably approximately 1 to 10 amino acids, and most preferably several (1 to 5) amino acids
  • the C-terminus may be in any form of a carboxyl group (—COOH), carboxylate (—COO ⁇ ), an amide (—CONH 2 ) or an ester (—COOR).
  • the partial peptide may be amidated or esterified and such an amide or ester is also included within the partial peptide of the present invention.
  • the ester group may be the same group as that described with respect to the C-terminus described above.
  • the partial peptide of the present invention further includes those in which the amino group of the amino acid residue of the N-terminal methionine residue is protected by a protecting group, those in which the N-terminal residue is cleaved in vivo and the produced glutamine residue is pyroglutaminated, those in which substituents on the side chains of amino acids in the molecule are protected by appropriate protecting groups, conjugated peptides such as so-called glycopeptides, to which sugar chains are bound, and the like.
  • physiologically acceptable salts with acids or bases especially physiologically acceptable acid addition salts.
  • the salts include salts with, for example, inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid); salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid
  • organic acids e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzen
  • GPR39 or salts thereof may be manufactured by a publicly known method used to purify receptor proteins from human or mammalian cells or tissues described above, or by culturing a transformant that contains the DNA encoding GPR39, as will be later described. Furthermore, GPR39 or its salts may also be manufactured by the methods for synthesizing proteins or by modifications thereof, which will also be described hereinafter.
  • GPR39 or its salts are produced from human or mammalian tissues or cells
  • human or mammalian tissues or cells are homogenized, then extracted with an acid or the like, and the extract is isolated and purified by a combination of chromatography techniques such as reverse phase chromatography, ion exchange chromatography, and the like.
  • resins that are used for protein synthesis may be used.
  • resins include chloromethyl resin, hydroxymethyl resin, benzhydrylamine resin, aminomethyl resin, 4-benzyloxybenzyl alcohol resin, 4-methylbenzhydrylamine resin, PAM resin, 4-hydroxymethylmehtylphenyl acetamidomethyl resin, polyacrylamide resin, 4-(2′,4′-dimethoxyphenylhydroxy-methyl)phenoxy resin, 4-(2′,4′-dimethoxyphenyl-Fmoc-aminoethyl) phenoxy resin, etc.
  • amino acids in which ⁇ -amino groups and functional groups on the side chains are appropriately protected are condensed on the resin in the order of the sequence of the objective protein according to various condensation methods publicly known in the art.
  • the protein is cut out from the resin and at the same time, the protecting groups are removed.
  • intramolecular disulfide bond-forming reaction is performed in a highly diluted solution to obtain the objective protein or its amides.
  • a variety of activation reagents for protein synthesis may be used, and carbodiimides are particularly preferable.
  • carbodiimides include DCC, N,N′-diisopropylcarbodiimide, N-ethyl-N′-(3-dimethylaminoprolyl)carbodiimide, etc.
  • a racemization inhibitor e.g., HOBt, HOOBt
  • the protected amino acids are added directly to the resin, or the protected amino acids are previously activated in the form of symmetric acid anhydrides, HOBt esters or HOOBt esters, followed by adding the thus activated protected amino acids to the resin.
  • Solvents suitable for use to activate the protected amino acids or condense with the resin may be chosen from solvents known to be usable for protein condensation reactions.
  • solvents include acid amides such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, etc.; alcohols such as trifluoroethanol, etc.; sulfoxides such as dimethylsulfoxide, etc.; ethers such as pyridine, dioxane, tetrahydrofuran, etc.; nitriles such as acetonitrile, propionitrile, etc.; esters such as methyl acetate, ethyl acetate, etc.; and appropriate mixtures of these solvents.
  • the reaction temperature is appropriately chosen from the range known to be applicable to protein binding reactions and is usually selected in the range of approximately ⁇ 20° C. to 50° C.
  • the activated amino acid derivatives are used generally in an excess of 1.5 to 4 times.
  • the condensation is examined by a test using the ninhydrin reaction; when the condensation is insufficient, the condensation can be completed by repeating the condensation reaction without removal of the protecting groups. When the condensation is yet insufficient even after repeating the reaction, unreacted amino acids are acetylated with acetic anhydride or acetylimidazole.
  • Examples of the protecting groups used to protect the amino groups of the starting compounds include Z, Boc, t-pentyloxycarbonyl, isobornyloxycarbonyl, 4-methoxybenzyloxycarbonyl, Cl-Z, Br-Z, adamantyloxycarbonyl, trifluoroacetyl, phthaloyl, formyl, 2-nitrophenylsulphenyl, diphenylphosphinothioyl, Fmoc, etc.
  • a carboxyl group can be protected by, e.g., alkyl esterification (in the form of linear, branched or cyclic alkyl esters of the alkyl moiety such as methyl, ethyl, propyl, butyl, t-butyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 2-adamantyl, etc.), aralkyl esterification (e.g., esterification in the form of benzyl ester, 4-nitrobenzyl ester, 4-methoxybenzyl ester, 4-chlorobenzyl ester, benzhydryl ester, etc.), phenacyl esterification, benzyloxycarbonyl hydrazidation, t-butoxycarbonyl hydrazidation, trityl hydrazidation, or the like.
  • alkyl esterification in the form of linear, branched
  • the hydroxyl group of serine can be protected through, for example, its esterification or etherification.
  • groups appropriately used for the esterification include a lower alkanoyl group, such as acetyl group, an aroyl group such as benzoyl group, and a group derived from carbonic acid such as benzyloxycarbonyl group, ethoxycarbonyl group, etc.
  • groups appropriately used for the etherification include benzyl group, tetrahydropyranyl group, t-butyl group, etc.
  • Examples of groups for protecting the phenolic hydroxyl group of tyrosine include Bzl, Cl 2 -Bzl, 2-nitrobenzyl, Br-Z, t-butyl, etc.
  • Examples of groups used to protect the imidazole moiety of histidine include Tos, 4-methoxy-2,3,6-trimethylbenzenesulfonyl, DNP, benzyloxymethyl, Burn, Boc, Trt, Fmoc, etc.
  • activated carboxyl groups used in the starting compounds include the corresponding acid anhydrides, azides, activated esters [esters with alcohols (e.g., pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethyl alcohol, p-nitrophenol, HONB, N-hydroxysuccimide, N-hydroxyphthalimide, HOBt)], etc.
  • alcohols e.g., pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethyl alcohol, p-nitrophenol, HONB, N-hydroxysuccimide, N-hydroxyphthalimide, HOBt
  • the activated amino acids in which the amino groups are activated in the starting material, for example, the corresponding phosphoric amides are employed.
  • the protecting groups there are used catalytic reduction under hydrogen gas flow in the presence of a catalyst such as Pd-black, Pd-carbon, etc.; an acid treatment with anhydrous hydrogen fluoride, methanesulfonic acid, trifluoromethane-sulfonic acid or trifluoroacetic acid, or a mixture solution of these acids; a treatment with a base such as diisopropylethylamine, triethylamine, piperidine, piperazine, etc.; and reduction with sodium in liquid ammonia.
  • the elimination of the protecting group by the acid treatment described above is carried out generally at a temperature of approximately ⁇ 20° C. to 40° C.
  • a cation scavenger such as anisole, phenol, thioanisole, m-cresol, p-cresol, dimethylsulfide, 1,4-butanedithiol, 1,2-ethanedithiol, etc.
  • 2,4-dinitrophenyl group known as the protecting group for the imidazole of histidine is removed by a treatment with thiophenol.
  • Formyl group used as the protecting group of the indole of tryptophan is eliminated by the aforesaid acid treatment in the presence of 1,2-ethanedithiol, 1,4-butanedithiol, etc. as well as by a treatment with an alkali such as a dilute sodium hydroxide solution, dilute ammonia, etc.
  • Protection of the functional groups that should not be involved in the reaction of the starting materials, protecting groups, elimination of the protecting groups, activation of functional groups involved in the reaction, or the like may be appropriately selected from publicly known groups and publicly known means.
  • the ⁇ -carboxyl group of the carboxy terminal amino acid is first protected by amidation; the peptide (protein) chain is then extended from the amino group side to a desired length. Thereafter, a protein in which only the protecting group of the N-terminal ⁇ -amino group in the peptide chain has been eliminated from the protein and a protein in which only the protecting group of the C-terminal carboxyl group has been eliminated are prepared.
  • the two proteins are condensed in a mixture of the solvents described above. The details of the condensation reaction are the same as described above.
  • the protected protein obtained by the condensation is purified, all the protecting groups are eliminated by the method described above to give the desired crude protein. This crude protein is purified by various known purification means. Lyophilization of the major fraction gives the amide of the desired protein.
  • esterified protein for example, the ⁇ -carboxyl group of the carboxy terminal amino acid is condensed with a desired alcohol to prepare the amino acid ester, which is followed by procedure similar to the preparation of the amidated protein above to give the ester form of the desired protein.
  • the partial peptide or its salts in GPR39 can be manufactured by publicly known methods for peptide synthesis, or by cleaving GPR39 with an appropriate peptidase.
  • methods for peptide synthesis for example, either solid phase synthesis or liquid phase synthesis may be used. That is, the partial peptide or amino acids that can construct GPR39 are condensed with the remaining part. Where the product contains protecting groups, these protecting groups are removed to give the desired peptide.
  • Publicly known methods for condensation and elimination of the protecting groups are described in a)-e) below.
  • the product may be purified and isolated by a combination of conventional purification methods such as solvent extraction, distillation, column chromatography, liquid chromatography and recrystallization to give the partial peptide of the present invention.
  • the partial peptide obtained by the methods above is in a free form, the peptide can be converted into an appropriate salt by a publicly known method; conversely when the peptide is obtained in a salt form, it can be converted into a free form by a publicly known method.
  • the polynucleotide encoding GPR39 may be any polynucleotide so long as it contains the base sequence (DNA or RNA, preferably DNA) encoding GPR39 described above. Such a polynucleotide may also be any one of DNA encoding GPR39, RNA such as mRNA, etc., and may be double-stranded or single-stranded. Where the polynucleotide is double-stranded, it may be double-stranded DNA, double-stranded RNA or DNA:RNA hybrid. Where the polynucleotide is single-stranded, it may be a sense strand (i.e., a coding strand) or an antisense strand (i.e., a non-coding strand).
  • mRNA of GPR39 can be quantified by, for example, the publicly known method published in separate volume of Jikken Igaku, 15 (7) “New PCR and its application” (1997), or by its modifications.
  • the DNA encoding GPR39 may be any of genomic DNA, genomic DNA library, cDNA derived from the cells and tissues described above, cDNA library derived from the cells and tissues described above and synthetic DNA.
  • the vector to be used for the library may be any of bacteriophage, plasmid, cosmid and phagemid.
  • the DNA may also be directly amplified by reverse transcriptase polymerase chain reaction (hereinafter abbreviated as RT-PCR) using the total RNA or mRNA fraction prepared from the cells and tissues described above.
  • the DNA encoding GPR39 may be any DNA, so long as it is, for example, a DNA containing the base sequence represented by SEQ ID NO: 2, or any DNA having a base sequence hybridizable to the base sequence represented by SEQ ID NO: 2 under high stringent conditions and encoding a receptor protein, which has the activity substantially equivalent to that of GPR39 consisting of the amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 (e.g., the ligand-binding activities, the signal transduction activities, cytokine (e.g., IL-8) secretion-promoting activities, etc.).
  • Examples of the DNA hybridizable to the DNA containing the base sequence represented by SEQ ID NO: 2 include a DNA containing a base sequence having at least about 80% homology, preferably at least about 90% homology and more preferably at least about 95% homology, to the base sequence represented by SEQ ID NO: 2.
  • the hybridization can be carried out by publicly known methods or by modifications of these methods, for example, according to the method described in Molecular Cloning, 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989).
  • a commercially available library may also be used according to the instructions of the attached manufacturer's protocol.
  • the hybridization can be carried out under highly stringent conditions.
  • the highly stringent conditions used herein are, for example, those in a sodium concentration at about 19 to 40 mM, preferably about 19 to 20 mM at a temperature of about 50 to 70° C., preferably about 60 to 65° C.
  • hybridization conditions in a sodium concentration of about 19 mM at a temperature of about 65° C. are most preferred.
  • DNA encoding human GPR39 containing the amino acid sequence represented by SEQ ID NO: 1 there may be employed a DNA containing the base sequence represented by SEQ ID NO: 2; etc.
  • DNA encoding mouse GPR39 containing the amino acid sequence represented by SEQ ID NO: 6 there may be employed a DNA containing the base sequence represented by SEQ ID NO: 7; etc.
  • DNA encoding rat GPR39 containing the amino acid sequence represented by SEQ ID NO: 8 there may be employed a DNA containing the base sequence represented by SEQ ID NO: 9; etc.
  • polynucleotide comprising a part of the base sequence of the DNA encoding GPR39 or a part of the base sequence complementary to the DNA is used to mean that the polynucleotide embraces not only the DNA encoding the partial peptide of the present invention described below but also RNA.
  • antisense polynucleotides that can inhibit the replication or expression of GPR39 gene can be designed and synthesized based on the base sequence information of the cloned or determined DNA encoding GPR39.
  • a polynucleotide is capable of hybridizing to RNA of GPR39 gene to inhibit the synthesis or function of said RNA or capable of modulating or controlling the expression of GPR39 gene via interaction with GPR39-associated RNA.
  • Polynucleotides complementary to the selected sequences of GPR39-associated RNA and polynucleotides specifically hybridizable to the GPR39-associated RNA are useful in modulating or controlling the expression of GPR39 gene in vivo and in vitro, and useful for the treatment or diagnosis of diseases.
  • the term “corresponding” is used to mean homologous to or complementary to a particular sequence of the nucleotide, base sequence or nucleic acid including the gene.
  • the term “corresponding” between nucleotides, base sequences or nucleic acids and peptides (proteins) usually refer to amino acids of a peptide (protein) under the order derived from the sequence of nucleotides (nucleic acids) or their complements.
  • the 5′ end hairpin loop, 5′ end 6-base-pair repeats, 5′ end untranslated region, polypeptide translation initiation codon, protein coding region, ORF translation initiation codon, 3′ end untranslated region, 3′ end palindrome region, and 3′ end hairpin loop may be selected as preferred target regions, though any other region may be selected as a target in GPR39 genes.
  • the relationship between the targeted nucleic acids and the polynucleotides complementary to at least a part of the target, specifically the relationship between the target and the polynucleotides hybridizable to the target, can be denoted to be “antisense”.
  • antisense polynucleotides examples include polydeoxyribonucleotide containing 2-deoxy-D-ribose, polyribonucleotide containing D-ribose, any other type of polynucleotides which are N-glycosides of a purine or pyrimidine base, or other polymers containing non-nucleotide backbones (e.g., protein nucleic acids and synthetic sequence-specific nucleic acid polymers commercially available) or other polymers containing nonstandard linkages (provided that the polymers contain nucleotides having such a configuration that allows base pairing or base stacking, as is found in DNA or RNA), etc.
  • non-nucleotide backbones e.g., protein nucleic acids and synthetic sequence-specific nucleic acid polymers commercially available
  • nonstandard linkages provided that the polymers contain nucleotides having such a configuration that allows base pairing or base stacking, as is found in DNA or RNA
  • They may be double-stranded DNA, single-stranded DNA, single-stranded RNA or a DNA:RNA hybrid, and may further include unmodified polynucleotides (or unmodified oligonucleotides), those with publicly known types of modifications, for example, those with labels known in the art, those with caps, methylated polynucleotides, those with substitution of one or more naturally occurring nucleotides by their analogue, those with intramolecular modifications of nucleotides such as those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.) and those with charged linkages or sulfur-containing linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those having side chain groups such as proteins (nucleases, nuclease inhibitors, toxins, antibodies, signal peptides, poly-L-lysine, etc.), saccharides (
  • nucleoside refers to moieties that contain not only the purine and pyrimidine bases, but also other heterocyclic bases, which have been modified. Such modifications may include methylated purines and pyrimidines, acylated purines and pyrimidines and other heterocyclic rings. Modified nucleotides and modified nucleotides also include modifications on the sugar moiety, wherein, for example, one or more hydroxyl groups may optionally be substituted with a halogen atom(s), an aliphatic group(s), etc., or may be converted into the corresponding functional groups such as ethers, amines, or the like.
  • the antisense polynucleotide (nucleic acid) of the present invention is RNA, DNA or a modified nucleic acid (RNA, DNA).
  • modified nucleic acid are, but not limited to, sulfur and thiophosphate derivatives of nucleic acids and those resistant to degradation of polynucleoside amides or oligonucleoside amides.
  • the antisense nucleic acids of the present invention can be modified preferably based on the following design, that is, by increasing the intracellular stability of the antisense nucleic acid, increasing the cellular permeability of the antisense nucleic acid, increasing the affinity of the nucleic acid to the targeted sense strand to a higher level, or minimizing the toxicity, if any, of the antisense nucleic acid.
  • the antisense nucleic acid of the present invention may contain changed or modified sugars, bases or linkages.
  • the antisense nucleic acid may also be provided in a specialized form such as liposomes, microspheres, or may be applied to gene therapy, or may be provided in combination with attached moieties.
  • attached moieties include polycations such as polylysine that act as charge neutralizers of the phosphate backbone, or hydrophobic moieties such as lipids (e.g., phospholipids, cholesterols, etc.) that enhance the interaction with cell membranes or increase uptake of the nucleic acid.
  • lipids to be attached are cholesterols or derivatives thereof (e.g., cholesteryl chloroformate, cholic acid, etc.). These moieties may be attached to the nucleic acid at the 3′ or 5′ ends thereof and may also be attached thereto through a base, sugar, or intramolecular nucleoside linkage. Other moieties may be capping groups specifically placed at the 3′ or 5′ ends of the nucleic acid to prevent degradation by nucleases such as exonuclease, RNase, etc. Such capping groups include, but are not limited to, hydroxyl protecting groups known in the art, including glycols such as polyethylene glycol, tetraethylene glycol and the like.
  • the inhibitory action of the antisense nucleic acid can be examined using the transformant of the present invention, the gene expression system of the present invention in vivo and in vitro, or the translation system of the G protein-coupled receptor protein in vivo and in vitro.
  • the nucleic acid can be applied to cells by a variety of publicly known methods.
  • the DNA encoding the partial peptide of the present invention may be any DNA so long as it contains the base sequence encoding the partial peptide of the present invention described above.
  • the DNA may also be any of genomic DNA, genomic DNA library, cDNA derived from the cells and tissues described above, cDNA library derived from the cells and tissues described above and synthetic DNA.
  • the vector to be used for the library may be any of bacteriophage, plasmid, cosmid and phagemid.
  • the DNA may also be directly amplified by reverse transcriptase polymerase chain reaction (hereinafter abbreviated as RT-PCR) using mRNA fraction prepared from the cells and tissues described above.
  • RT-PCR reverse transcriptase polymerase chain reaction
  • the DNA encoding the partial peptide of the present invention may be any one of, for example, (1) a DNA containing a partial base sequence of the DNA having the base sequence represented by SEQ ID NO: 2 or (2) any DNA containing a partial base sequence of the DNA having a base sequence hybridizable to the base sequence represented by SEQ ID NO: 2 under highly stringent conditions and encoding the receptor protein which has the activities substantially equivalent to those of GPR39 (e.g., a ligand-biding activity, signal transduction activity, cytokine (e.g., IL-8) secretion-promoting activity, etc.); etc.
  • GPR39 e.g., a ligand-biding activity, signal transduction activity, cytokine (e.g., IL-8) secretion-promoting activity, etc.
  • Examples of the DNA that is hybridizable to the base sequence represented by SEQ ID NO: 2 include DNA comprising a base sequence having at least about 80% homology, preferably at least about 90% homology and more preferably at least about 95% homology, to the base sequence represented by SEQ ID NO: 2.
  • homology scoring algorithm NCBI BLAST described above.
  • the DNA may be amplified by PCR using synthetic DNA primers containing a part of the base sequence of DNA encoding GPR39, or the DNA inserted into an appropriate vector can be selected by hybridization with a labeled DNA fragment or synthetic DNA that encodes a part or entire region of GPR39.
  • the hybridization can be carried out, for example, according to the method described in Molecular Cloning, 2nd, J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989.
  • the hybridization may also be performed using commercially available library in accordance with the protocol described in the attached instructions.
  • Conversion of the base sequence of the DNA can be effected by publicly known methods such as the ODA-LA PCR method, the Gapped duplex method or the Kunkel method or its modification by using a publicly known kit available as MutanTM-superExpressKm (manufactured by Takara Shuzo Co., Ltd.), MutanTM-K (manufactured by TaKaRa Shuzo Co., Ltd.), etc.
  • publicly known methods such as the ODA-LA PCR method, the Gapped duplex method or the Kunkel method or its modification by using a publicly known kit available as MutanTM-superExpressKm (manufactured by Takara Shuzo Co., Ltd.), MutanTM-K (manufactured by TaKaRa Shuzo Co., Ltd.), etc.
  • the cloned DNA encoding GPR39 can be used as it is, depending upon purpose or, if desired, after digestion with a restriction enzyme or after the addition of a linker thereto.
  • the DNA may contain ATG as a translation initiation codon at the 5′ end thereof and may further contain TAA, TGA or TAG as a translation termination codon at the 3′ end thereof. These translation initiation and termination codons may also be added by using an appropriate synthetic DNA adapter.
  • the expression vector for GPR39 can be manufactured, for example, by (a) excising the desired DNA fragment from the DNA encoding GPR39, and then (b) ligating the DNA fragment with an appropriate expression vector downstream a promoter in the vector.
  • Examples of the vector include plasmids derived form E. coli (e.g., pBR322, pBR325, pUC12, pUC13), plasmids derived from Bacillus subtilis (e.g., pUB110, pTP5, pC194), plasmids derived from yeast (e.g., pSH19, pSH15), bacteriophages such as ⁇ phage, etc., animal viruses such as retrovirus, vaccinia virus, baculovirus, etc. as well as pA1-11, pXT1, pRc/CMV, pRc/RSV, pcDNAI/Neo, etc.
  • E. coli e.g., pBR322, pBR325, pUC12, pUC13
  • Bacillus subtilis e.g., pUB110, pTP5, pC194
  • yeast e.g., pSH19,
  • the promoter used in the present invention may be any promoter if it matches well with a host to be used for gene expression.
  • examples of the promoter include SR ⁇ promoter, SV40 promoter, LTR promoter, CMV promoter, HSV-TK promoter, etc.
  • CMV promoter or SR ⁇ promoter is preferably used.
  • the host is bacteria of the genus Escherichia
  • preferred examples of the promoter include trp promoter, lac promoter, recA promoter, ⁇ P L promoter, lpp promoter, etc.
  • preferred example of the promoter are SPO1 promoter, SPO2 promoter, penP promoter, etc.
  • preferred examples of the promoter are PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, etc.
  • preferred examples of the promoter include polyhedrin prompter, P10 promoter, etc.
  • the expression vector may further optionally contain an enhancer, a splicing signal, a polyA addition signal, a selection marker, SV40 replication origin (hereinafter sometimes abbreviated as SV40ori) etc.
  • the selection marker include dihydrofolate reductase (hereinafter sometimes abbreviated as dhfr) gene [methotrexate (MTX) resistance], ampicillin resistant gene (hereinafter sometimes abbreviated as Amp r ), neomycin resistant gene (hereinafter sometimes abbreviated as Neo r , G418 resistance), etc.
  • dhfr gene when dhfr gene is used as the selection marker in CHO (dhfr ⁇ ) cells, selection can also be made on thymidine free media.
  • a signal sequence that matches with a host is added to the N-terminus of the receptor protein of the present invention.
  • the signal sequence that can be used are Pho A signal sequence, OmpA signal sequence, etc. in the case of using bacteria of the genus Escherichia as the host; ⁇ -amylase signal sequence, subtilisin signal sequence, etc. in the case of using bacteria of the genus Bacillus as the host; MF ⁇ signal sequence, SUC2 signal sequence, etc. in the case of using yeast as the host; and insulin signal sequence, ⁇ -interferon signal sequence, antibody molecule signal sequence, etc. in the case of using animal cells as the host, respectively.
  • transformants can be manufactured.
  • Examples of the host which may be employed, are bacteria belonging to the genus Escherichia , bacteria belonging to the genus Bacillus , yeast, insect cells, insects and animal cells, etc.
  • bacteria belonging to the genus Escherichia include Escherichia coli K12 DH1 [Proc. Natl. Acad. Sci. U.S.A., 60, 160 (1968)), JM103 (Nucleic Acids Research, 9, 309 (1981)], JA221 [Journal of Molecular Biology, 120, 517 (1978)], HB101 [Journal of Molecular Biology, 41, 459 (1969)), C600 (Genetics, 39, 440 (1954)], etc.
  • Bacillus subtilis M114 Gene, 24, 255 (1983)]
  • 207-21 Journal of Biochemistry, 95, 87 (1984)]
  • yeast examples include Saccharomyces cereviseae AH22, AH22R ⁇ , NA87-11A, DKD-5D, 20B-12, Schizosaccharomyces pombe NCYC1913, NCYC2036, Pichia pastoris , etc.
  • insect cells examples include, for the virus AcNPV, Spodoptera frugiperda cells (Sf cells), MG1 cells derived from mid-intestine of Trichoplusia ni , High FiveTM cells derived from egg of Trichoplusia ni , cells derived from Mamestra brassicae , cells derived from Estigmena acrea, etc.; and for the virus BmNPV, Bombyx mori N cells (BmN cells), etc. are used.
  • Sf cell which can be used are Sf9 cells (ATCC CRL1711) and Sf21 cells (both cells are described in Vaughn, J. L. et al., In Vivo, 13, 213-217 (1977)).
  • a larva of Bombyx mori can be used [Maeda, et al., Nature, 315, 592 (1985)].
  • animal cells examples include monkey cells COS-7, Vero, Chinese hamster cells CHO (hereinafter referred to as CHO cells), dhfr gene deficient Chinese hamster cells CHO (hereinafter simply referred to as CHO(dhfr ⁇ ) cell), mouse L cells, mouse AtT-20, mouse myeloma cells, rat GH3, human FL cells, etc.
  • Bacteria belonging to the genus Escherichia can be transformed, for example, by the method described in Proc. Natl. Acad. Sci. U.S.A., 69, 2110 (1972), Gene, 17, 107 (1982), etc.
  • Bacteria belonging to the genus Bacillus can be transformed, for example, by the method described in Molecular & General Genetics, 168, 111 (1979).
  • Yeast can be transformed, for example, by the method described in Methods in Enzymology, 194, 182-187 (1991), Proc. Natl. Acad. Sci. U.S.A., 75, 1929 (1978), etc.
  • Insect cells or insects can be transformed, for example, according to the method described in Bio/Technology, 6, 47-55(1988), etc.
  • Animal cells can be transformed, for example, according to the method described in Saibo Kogaku (Cell Engineering), extra issue 8 , Shin Saibo Kogaku Jikken Protocol (New Cell Engineering Experimental Protocol), 263-267 (1995), published by Shujunsha, or Virology, 52, 456 (1973).
  • the transformant transformed with the expression vector containing the DNA encoding GPR39 can be obtained.
  • the transformant can be appropriately incubated in a liquid medium which contains materials required for growth of the transformant such as carbon sources, nitrogen sources, inorganic materials, and so on.
  • materials required for growth of the transformant such as carbon sources, nitrogen sources, inorganic materials, and so on.
  • the carbon sources include glucose, dextrin, soluble starch, sucrose, etc.
  • the nitrogen sources include inorganic or organic materials such as ammonium salts, nitrate salts, corn steep liquor, peptone, casein, meat extract, soybean cake, potato extract, etc.
  • the inorganic materials are calcium chloride, sodium dihydrogenphosphate, magnesium chloride, etc.
  • yeast extract, vitamins, growth promoting factors etc. may also be added to the medium.
  • pH of the medium is adjusted to about 5 to about 8.
  • a preferred example of the medium for incubation of the bacteria belonging to the genus Escherichia is M9 medium supplemented with glucose and Casamino acids (Miller, Journal of Experiments in Molecular Genetics, 431-433, Cold Spring Harbor Laboratory, New York, 1972). If necessary, a chemical such as 3 ⁇ -indolylacrylic acid can be added to the medium thereby to activate the promoter efficiently.
  • the transformant is usually cultivated at about 15 to 43° C. for about 3 hours to about 24 hours. If necessary, the culture may be aerated or agitated.
  • the transformant is cultivated generally at about 30 to 40° C. for about 6 to 24 hours. If necessary, the culture can be aerated or agitated.
  • the transformant is cultivated, for example, in Burkholder's minimal medium [Bostian, K. L. et al., Proc. Natl. Acad. Sci. U.S.A., 77, 4505 (1980)] or in SD medium supplemented with 0.5% Casamino acids [Bitter, G. A. et al., Proc. Natl. Acad. Sci. U.S.A., 81, 5330 (1984)].
  • pH of the medium is adjusted to about 5 to about 8.
  • the transformant is cultivated at about 20° C. to about 35° C. for about 24 to 72 hours. If necessary, the culture can be aerated or agitated.
  • the transformant is cultivated in, for example, Grace's Insect Medium (Grace, T. C. C., Nature, 195, 788 (1962)) to which an appropriate additive such as immobilized 10% bovine serum is added.
  • pH of the medium is adjusted to about 6.2 to about 6.4.
  • the transformant is cultivated at about 27° C. for about 3 days to about 5 days and, if necessary and desired, the culture can be aerated or agitated.
  • the transformant is cultivated in, for example, MEM medium containing about 5% to about 20% fetal bovine serum [Science, 122, 501 (1952)], DMEM medium [Virology, 8, 396 (1959)], RPMI 1640 medium [The Journal of the American Medical Association, 199, 519 (1967)], 199 medium [Proceeding of the Society for the Biological Medicine, 73, 1 (1950)], etc.
  • pH of the medium is adjusted to about 6 to about 8.
  • the transformant is usually cultivated at about 30° C. to about 40° C. for about 15 hours to about 60 hours and, if necessary and desired, the culture can be aerated or agitated.
  • GPR39 can be produced into the cell, in the cell membrane or out of the cell of the transformant.
  • GPR39 can be separated and purified from the culture described above by the following procedures.
  • GPR39 When GPR39 is extracted from the culture or cells, after cultivation the transformants or cells are collected by a publicly known method and suspended in an appropriate buffer. The transformants or cells are then disrupted by publicly known methods such as ultrasonication, a treatment with lysozyme and/or freeze-thaw cycling, followed by centrifugation, filtration, etc. Thus, the crude extract of GPR39 can be obtained.
  • the buffer used for the procedures may contain a protein modifier such as urea or guanidine hydrochloride, or a surfactant such as Triton X-100TM, etc.
  • GPR39 contained in the supernatant or the extract thus obtained can be purified by appropriately combining the publicly known methods for separation and purification.
  • Such publicly known methods for separation and purification include a method utilizing difference in solubility such as salting out, solvent precipitation, etc.; a method utilizing mainly difference in molecular weight such as dialysis, ultrafiltration, gel filtration, SDS-polyacrylamide gel electrophoresis, etc.; a method utilizing difference in electric charge such as ion exchange chromatography, etc.; a method utilizing difference in specific affinity such as affinity chromatography, etc.; a method utilizing difference in hydrophobicity such as reverse phase high performance liquid chromatography, etc.; a method utilizing difference in isoelectric point such as isoelectrofocusing electrophoresis; and the like.
  • GPR39 thus obtained is in a free form, it can be converted into the salt by publicly known methods or modifications thereof.
  • GPR39 when GPR39 is obtained in the form of a salt, it can be converted into the free form or in the form of a different salt by publicly known methods or modifications thereof.
  • GPR39 produced by the recombinant can be treated, prior to or after the purification, with an appropriate protein modifying enzyme so that GPR39 can be appropriately modified to partially remove a polypeptide.
  • protein-modifying enzyme include trypsin, chymotrypsin, arginyl endopeptidase, protein kinase, glycosidase or the like.
  • the activity of the thus produced GPR39 can be determined by a binding experiment to a labeled ligand, by an enzyme immunoassay using a specific antibody, or the like.
  • Antibodies to GPR39 may be any of polyclonal antibodies and monoclonal antibodies, as long as they are capable of recognizing GPR39.
  • the antibodies to GPR39 may be manufactured by publicly known methods for manufacturing antibodies or antisera, using as antigens GPR39.
  • GPR39 is administered to mammals either solely or together with carriers or diluents to the site where the production of antibody is possible by the administration.
  • complete Freund's adjuvants or incomplete Freund's adjuvants may be administered.
  • the administration is usually carried out once in every two to six weeks and 2 to 10 times in total. Examples of the applicable mammals are monkeys, rabbits, dogs, guinea pigs, mice, rats, sheep and goats, with mice and rats being preferred.
  • mice In the preparation of monoclonal antibody-producing cells, warm-blooded animals, e.g., mice, immunized with an antigen wherein the antibody titer is noted is selected, then the spleen or lymph node is collected after 2 to 5 days from the final immunization and antibody-producing cells contained therein are fused with myeloma cells to give monoclonal antibody-producing hybridomas.
  • Measurement of the antibody titer in antisera may be made, for example, by reacting a labeled form of the receptor protein, which will be described later, with the antiserum followed by assaying the binding activity of the labeling agent bound to the antibody.
  • the fusion may be operated, for example, by the known Koehler and Milstein method [Nature, 256, 495 (1975)].
  • the fusion accelerator are polyethylene glycol (PEG), Sendai virus, etc., of which PEG is preferably employed.
  • Examples of the myeloma cells are NS-1, P3U1, SP2/0, etc.
  • P3U1 is preferably employed.
  • a preferred ratio of the count of the antibody-producing cells used (spleen cells) to the count of myeloma cells is within a range of approximately 1:1 to 20:1.
  • PEG preferably, PEG 1000 to PEG 6000
  • PEG is added in a concentration of approximately 10 to 80% followed by incubating at about 20 to about 40° C., preferably at about 30 to about 37° C. for about 1 to about 10 minutes, an efficient cell fusion can be carried out.
  • Various methods can be used for screening of a monoclonal antibody-producing hybridoma.
  • examples of such methods include a method which comprises adding the supernatant of hybridoma to a solid phase (e.g., microplate) adsorbed with an antigen of the receptor protein directly or together with a carrier, adding an anti-immunoglobulin antibody (when mouse cells are used for the cell fusion, anti-mouse immunoglobulin antibody is used) labeled with a radioactive substance or an enzyme, or Protein A and detecting the monoclonal antibody bound to the solid phase, and a method which comprises adding the supernatant of hybridoma to a solid phase adsorbed with an anti-immunoglobulin antibody or Protein A, adding the receptor protein labeled with a radioactive substance or an enzyme and detecting the monoclonal antibody bound to the solid phase.
  • the monoclonal antibody can be selected by publicly known methods or by modifications of these methods. In general, the selection can be effected in a medium for animal cells supplemented with HAT (hypoxanthine, aminopterin and thymidine). Any selection and growth medium can be employed as far as the hybridoma can grow therein.
  • HAT hyperxanthine, aminopterin and thymidine
  • Any selection and growth medium can be employed as far as the hybridoma can grow therein.
  • RPMI 1640 medium containing 1% to 20%, preferably 10% to 20% fetal bovine serum, GIT medium (Wako Pure Chemical Industries, Ltd.) containing 1% to 10% fetal bovine serum, a serum free medium for cultivation of a hybridoma (SFM-101, Nissui Seiyaku Co., Ltd.) and the like can be used for the selection and growth medium.
  • the cultivation is carried out generally at 20° C. to 40° C., preferably at about 37° C., for 5 days to 3 weeks, preferably 1 to 2 weeks.
  • the cultivation can be conducted normally in 5% CO 2 .
  • the antibody titer of the culture supernatant of hybridomas can be determined as in the assay for the antibody titer in antisera described above.
  • Separation and purification of a monoclonal antibody can be carried out by methods applied to conventional separation and purification of immunoglobulins, as in the conventional methods for separation and purification of polyclonal antibodies [e.g., salting-out, alcohol precipitation, isoelectric point precipitation, electrophoresis, adsorption and desorption with ion exchangers (e.g., DEAE), ultracentrifugation, gel filtration, or a specific purification method which comprises collecting only an antibody with an activated adsorbent such as an antigen-binding solid phase, Protein A, Protein G. etc. and dissociating the binding to obtain the antibody].
  • an activated adsorbent such as an antigen-binding solid phase, Protein A, Protein G. etc.
  • the polyclonal antibody of the present invention can be manufactured by publicly known methods or modifications thereof.
  • a complex of immunogen (GPR39 antigen) and a carrier protein is prepared, and a mammal is immunized with the complex in a manner similar to the method described above for the manufacture of monoclonal antibodies.
  • the product containing the antibody to GPR39 is collected from the immunized animal followed by separation and purification of the antibody.
  • the type of carrier protein and the mixing ratio of a carrier to hapten may be any type and in any ratio, as long as the antibody is efficiently produced to the hapten immunized by crosslinking to the carrier.
  • bovine serum albumin, bovine thyroglobulins, keyhole limpet hemocyanin, etc. is coupled to hapten in a carrier-to-hapten weight ratio of approximately 0.1 to 20, preferably about 1 to about 5.
  • a variety of condensing agents can be used for the coupling of a carrier to hapten.
  • Glutaraldehyde, carbodiimide, maleimide activated ester, activated ester reagents containing thiol group or dithiopyridyl group, etc. are used for the coupling.
  • the condensation product is administered to warm-blooded animals either solely or together with carriers or diluents to the site in which the antibody can be produced by the administration.
  • complete Freund's adjuvant or incomplete Freund's adjuvant may be administered.
  • the administration is usually made once approximately in every 2 to 6 weeks and about 3 to about 10 times in total.
  • the polyclonal antibody can be collected from the blood, ascites, etc., preferably from the blood of mammals immunized by the method described above.
  • the polyclonal antibody titer in antiserum can be assayed by the same procedure as that for the determination of serum antibody titer described above.
  • the separation and purification of the polyclonal antibody can be carried out, following the method for the separation and purification of immunoglobulins performed as applied to the separation and purification of monoclonal antibodies described hereinabove.
  • the ligand for GPR39 is an ionizable metal element or salts thereof.
  • Examples of the ionizable metal element include zinc, copper, nickel, cadmium, and so on.
  • salts of these metal elements for example, salts with acids such as hydrochloric acid, sulfuric acid, nitric acid, acetic acid, etc., specifically preferred are cadmium chloride, zinc chloride, zinc acetate, copper chloride, copper sulfate, nickel chloride and nickel sulfate, etc. are used and more preferred are cadmium chloride, zinc chloride, copper chloride and nickel chloride.
  • the ionizable metal elements include (1) metal elements in an ionic state (e.g., zinc ions, copper ions, nickel ions and cadmium ions); (2) compounds containing the ionizable metal elements (e.g., oxides such as zinc oxide, copper oxide, nickel oxide and cadmium oxide), and the like.
  • metal elements in an ionic state e.g., zinc ions, copper ions, nickel ions and cadmium ions
  • compounds containing the ionizable metal elements e.g., oxides such as zinc oxide, copper oxide, nickel oxide and cadmium oxide
  • the ionizable metal elements such as cadmium, zinc, copper, nickel, etc., or salts thereof are merely referred to as the “metal elements” throughout the specification.
  • GPR39 the DNA encoding GPR39 (hereinafter sometimes referred to briefly as the DNA of the present invention), the antibody to GPR39 (hereinafter sometimes referred to briefly as the antibody of the present invention) and the antisense DNA to the DNA of the present invention (hereinafter sometimes referred to briefly as the antisense DNA of the present invention) have the following applications.
  • GPR39 or b) the DNA encoding GPR39 can be used as pharmaceutical drugs such as agents for preventing/treating diseases associated with dysfunction of GPR39, etc.
  • the amount of GPR39 can be increased in the body of the patient a) by administering GPR39 to the patient thereby to supplement the amount of GPR39; or b) (a) by administering the DNA encoding GPR39 to the patient to express the same, or (ii) by inserting and expressing the DNA encoding GPR39 in the objective cells and then transplanting the cells to the patient, whereby the activities of the ligand can be sufficiently exhibited. That is, the DNA encoding GPR39 is useful as a safe and low toxic agent for preventing/treating diseases associated with dysfunction of GPR39.
  • GPR39 or the DNA of the present invention can be used as a prophylactic/therapeutic agent for metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc., or an agent for promoting the secretion of cytokines (e.g., IL-8).
  • cytokines e.g.,
  • GPR39 is used as the preventive/therapeutic agent described above, GPR39 can be prepared into a pharmaceutical composition in a conventional manner.
  • the DNA of the present invention is used as the preventive/therapeutic agent described above
  • the DNA itself is administered alone; alternatively, the DNA is inserted into an appropriate vector such as retrovirus vector, adenovirus vector, adenovirus-associated virus vector, etc. and then administered in a conventional manner.
  • the DNA of the present invention may also be administered as naked DNA, or with adjuvants to assist its uptake by gene gun or through a catheter such as a catheter with a hydrogel.
  • a) GPR39 or b) the DNA of the present invention can be used orally, for example, in the form of tablets which may be sugar coated if necessary, capsules, elixirs, microcapsules etc., or parenterally in the form of injectable preparations such as a sterile solution and a suspension in water or with other pharmaceutically acceptable liquid.
  • injectable preparations such as a sterile solution and a suspension in water or with other pharmaceutically acceptable liquid.
  • These preparations can be manufactured by mixing a) GPR39 or b) the DNA of the present invention with a physiologically acceptable known carrier, a flavoring agent, an excipient, a vehicle, an antiseptic agent, a stabilizer, a binder, etc. in a unit dosage form required in a generally accepted manner that is applied to making pharmaceutical preparations.
  • the effective component in the preparation is controlled in such a dose that an appropriate dose is obtained within the specified range given.
  • Additives miscible with tablets, capsules, etc. include a binder such as gelatin, corn starch, tragacanth and gum arabic, an excipient such as crystalline cellulose, a puffiness agent such as corn starch, gelatin and alginic acid, a lubricant such as magnesium stearate, a sweetening agent such as sucrose, lactose and saccharin, and a flavoring agent such as peppermint, akamono oil and cherry.
  • a binder such as gelatin, corn starch, tragacanth and gum arabic
  • an excipient such as crystalline cellulose
  • a puffiness agent such as corn starch, gelatin and alginic acid
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose and saccharin
  • a flavoring agent such as peppermint, akamono oil and cherry.
  • liquid carriers such as oils and fats may further be used together with the
  • a sterile composition for injection may be formulated by conventional procedures used to make pharmaceutical compositions, e.g., by dissolving or suspending the active ingredients in a vehicle such as water for injection with a naturally occurring vegetable oil such as sesame oil and coconut oil, etc. to prepare the pharmaceutical composition.
  • an aqueous medium for injection examples include physiological saline and an isotonic solution containing glucose and other auxiliary agents (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.) and may be used in combination with an appropriate dissolution aid such as an alcohol (e.g., ethanol or the like), a polyalcohol (e.g., propylene glycol and polyethylene glycol), a nonionic surfactant (e.g., polysorbate 80TM and HCO-50), etc.
  • an alcohol e.g., ethanol or the like
  • a polyalcohol e.g., propylene glycol and polyethylene glycol
  • a nonionic surfactant e.g., polysorbate 80TM and HCO-50
  • the oily medium examples include sesame oil and soybean oil, which may also be used in combination with a dissolution aid such as benzyl benzoate and benzyl alcohol.
  • the preventive/therapeutic agent described above may further be formulated with a buffer (e.g., phosphate buffer, sodium acetate buffer, etc.), a soothing agent (e.g., benzalkonium chloride, procaine hydrochloride, etc.), a stabilizer (e.g., human serum albumin, polyethylene glycol, etc.), a preservative (e.g., benzyl alcohol, phenol, etc.), an antioxidant, etc.
  • a buffer e.g., phosphate buffer, sodium acetate buffer, etc.
  • a soothing agent e.g., benzalkonium chloride, procaine hydrochloride, etc.
  • a stabilizer e.g., human serum albumin, polyethylene glycol, etc.
  • a preservative e.g., benzyl alcohol, phenol, etc.
  • an antioxidant e.g., benzyl alcohol, phenol, etc.
  • the preparation can be administered to human or mammals (e.g., rats, mice, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.).
  • human or mammals e.g., rats, mice, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.
  • the dose of GPR39 varies depending on the subject to be administered, target organ, conditions, method for administration, etc.; in oral administration for the patient (as 60 kg body weight) with, e.g., cancer, the dose is normally about 0.1 mg to about 100 mg, preferably about 1.0 to about 50 mg, and more preferably about 1.0 to about 20 mg per day.
  • the single dose varies depending on the subject to be administered, target organ, conditions, method for administration, etc.
  • GPR39 intravenously to the patient with, e.g., cancer
  • a daily dose of about 0.01 to about 30 mg, preferably about 0.1 to about 20 mg, and more preferably about 0.1 to about 10 mg.
  • the corresponding dose as converted per 60 kg can be administered.
  • the dose of the DNA of the present invention varies depending on the subject to be administered, target organ, conditions, method for administration, etc.; in oral administration for the patient (as 60 kg body weight) with, e.g., cancer, the dose is normally about 0.1 mg to about 100 mg, preferably about 1.0 to about 50 mg, and more preferably about 1.0 to about 20 mg per day.
  • the single dose varies depending on the subject to be administered, target organ, conditions, method for administration, etc.
  • the DNA intravenously to the patient with, e.g., cancer in a daily dose of about 0.01 to about 30 mg, preferably about 0.1 to about 20 mg, and more preferably about 0.1 to about 10 mg.
  • the corresponding dose as converted per 60 kg can be administered.
  • an abnormality of the DNA or mRNA encoding GPR39 or its partial peptides in human or mammals (e.g., rats, mice, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.) can be detected, and are thus useful as gene diagnostic agents for the damage against the DNA or mRNA, its mutation, or its reduced expression, or increased expression or overexpression of the DNA or mRNA.
  • human or mammals e.g., rats, mice, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.
  • the gene diagnosis described above using the DNA, antisense DNA of the present invention can be performed by, for example, the publicly known Northern hybridization assay or the PCR-SSCP assay (Genomics, 5, 874-879 (1989); Proceedings of the National Academy of Sciences of the United States of America, 86, 2766-2770 (1989)), etc.
  • GPR39 a reduced expression or overexpression of GPR39 is detected by, e.g., northern hybridization, it can be diagnosed that one suffers from diseases associated with, for example, the dysfunction or excessive action of GPR39, or it is highly likely to suffer from these disease in the future.
  • the diseases associated with the dysfunction of GPR39 include metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc.
  • the diseases caused by the excessive action of GPR39 include, for example, excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria including interstitial cystitis, prostatic hyperplasia induced-pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms, various disorders caused by urinary calculus, etc., or inflammatory diseases (e.g., diabetic complications such as neuropathy, large vascular disorders, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases (e.g., asthma, atopic dermatitis or chronic obstructive pulmonary disease (COPD)); or the like.
  • excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease,
  • the DNA can be used for screening a compound or its salt that changes the expression level of GPR39.
  • the present invention provides methods of screening the compound or its salt that changes the expression level of GPR39, which comprises measuring the amount of mRNA in GPR39 contained in, for example, (i) a) blood, b) particular organs, c) tissues or cells isolated from the organs of non-human mammal or in (ii) transformants, etc.
  • the amount of mRNA in GPR39 can be measured as follows.
  • mice, rats, rabbits, sheep, swine, bovine, cats, dogs, monkeys, more specifically, immunodeficiency model rats, mice, rabbits, etc. receive a drug (e.g., an immunomodulator, etc.) or physical stress (e.g., soaking stress, electric shock, light and darkness, low temperature, etc.), and the blood, particular organs (e.g., brain, liver, kidney, etc.), or tissues or cells isolated from the organs are obtained after a specified period of time.
  • a drug e.g., an immunomodulator, etc.
  • physical stress e.g., soaking stress, electric shock, light and darkness, low temperature, etc.
  • the mRNA of GPR39 contained in the thus obtained cells is extracted from the cells, for example, in a conventional manner and quantified by means of, e.g., TaqManPCR, or may also be analyzed by northern blot technique by publicly known methods.
  • Transformants that express GPR39 are prepared according to the methods described above, and the mRNA of GPR39 can be quantified and analyzed, as described above.
  • the compound that changes the expression level of GPR39 can be screened by the following procedures.
  • a test compound is administered at a specified period of time before (30 minutes to 24 hours before, preferably 30 minutes to 12 hours before, more preferably 1 hour to 6 hours before), at a specified time after (30 minutes to 3 days after, preferably 1 hour to 2 days after, more preferably 1 hour to 24 hours after), or simultaneously with a drug or physical stress.
  • a specified time (30 minute to 3 days, preferably 1 hour to 2 days, more preferably 1 hour to 24 hours) after administration of the test compound, the amount of mRNA in GPR39 contained in cells are quantified and analyzed.
  • Transformants are cultured in a conventional manner and a test compound is mixed in the culture medium. After a specified time (after 1 day to 7 days, preferably after 1 day to 3 days, more preferably after 2 to 3 days), the amount of mRNA in GPR39 contained in the transformants can be quantified and analyzed.
  • test compounds include peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, blood plasma, etc. They may be novel or known compounds.
  • the test compound may form salts and may be used in the form of salts with physiologically acceptable acids (e.g., inorganic acids, etc.) or bases (e.g., organic acids, etc.), preferably physiologically acceptable acid addition salts.
  • physiologically acceptable acids e.g., inorganic acids, etc.
  • bases e.g., organic acids, etc.
  • physiologically acceptable acid addition salts examples include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydro
  • the compound which is obtained by the screening methods of the present invention, is the compound that changes the expression level of GPR39. Specifically, it is (a) the compound that potentiates the cell stimulating activities mediated by GPR39 (e.g., the activities that promote or suppress arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, alters in cell membrane potential, phosphorylation of intracellular proteins, activation of c-fos, pH reduction, etc.; an action of promoting the secretion of cytokines (e.g., IL-8), etc.; in particular, the intracellular Ca 2+ level increasing activity (intracellular Ca 2+ release activity), action of promoting the secretion of cytokines (e.g., IL-8)) by increasing the expression level of GPR39; and (b) the compound that attenuates the cell-stimulating activities by reducing the expression level of G
  • the compounds obtained by using the screening method of the present invention include peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, etc. They may be novel or known compounds.
  • salts of the compound obtained by the screening method of the present invention salts with physiologically acceptable acids (e.g., inorganic acids, etc.) or bases (e.g., organic acids, etc.) may be used and preferably used are physiologically acceptable acid addition salts.
  • physiologically acceptable acids e.g., inorganic acids, etc.
  • bases e.g., organic acids, etc.
  • salts examples include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
  • organic acids e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.
  • the ligand for GPR39 is the ionizable metal element such as cadmium, zinc, copper and nickel, or salts thereof.
  • the compound or its salts which are obtained by the screening method described above and change the expression level of GPR39, can be used as a prophylactic/therapeutic agent for diseases associated with the dysfunction of GPR39 (for example, metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc.), or diseases associated with the excessive action
  • the compound or its salts that increase the expression level of GPR39 can be used as a prophylactic/therapeutic agent for, for example, metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc., or as an agent for promoting the secretion of cytokines (e.g., IL-8).
  • the compound or its salts that decrease the expression level of GPR39 can be used as a prophylactic/therapeutic agent for, for example, excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria including interstitial cystitis, prostatic hyperplasia induced-pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms, various disorders caused by urinary calculus, etc., an agent for suppressing the secretion of cytokines (e.g., IL-8), or a prophylactic/therapeutic agent for inflammatory diseases (e.g., diabetic complications such as neuropathy, large vascular disorders, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases (e.g., asthma, a
  • the compound or its salt which is obtained by the screening methods of the present invention, is used as a pharmaceutical composition
  • the compound or its salt can be prepared into a pharmaceutical preparation in a conventional manner.
  • the compound can be used orally in the form of tablets which may be tablets, if necessary, coated with sugar, capsules, elixirs, microcapsules, etc., or parenterally in the form of injectable preparations such as a sterile solution or a suspension in water or with other pharmaceutically acceptable liquid.
  • injectable preparations such as a sterile solution or a suspension in water or with other pharmaceutically acceptable liquid.
  • These preparations can be manufactured, e.g., by mixing the compound, with a physiologically acceptable known carrier, flavoring agent, excipient, vehicle, antiseptic, stabilizer, binder, etc., in a unit dosage form required in a generally accepted manner applied to making pharmaceutical preparations.
  • the active ingredient in the preparation is controlled in such an amount that an appropriate dose is obtained within the specified range given.
  • Additives miscible with tablets, capsules, etc. include a binder such as gelatin, corn starch, tragacanth or gum arabic, an excipient such as crystalline cellulose, a puffiness agent such as corn starch, gelatin, alginic acid, etc., a lubricant such as magnesium stearate, a sweetening agent such as sucrose, lactose or saccharin, a flavoring agent such as peppermint, akamono oil or cherry, and the like.
  • a binder such as gelatin, corn starch, tragacanth or gum arabic
  • an excipient such as crystalline cellulose
  • a puffiness agent such as corn starch, gelatin, alginic acid, etc.
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin
  • a flavoring agent such as peppermint, akamono oil or cherry, and the like.
  • liquid carriers
  • a sterile composition for injection may be formulated following a conventional manner used to make pharmaceutical compositions, e.g., by dissolving or suspending the active ingredients in a vehicle such as water for injection with a naturally occurring vegetable oil such as sesame oil, coconut oil, etc. to prepare the pharmaceutical composition.
  • an aqueous medium for injection examples include physiological saline, an isotonic solution containing glucose and other auxiliary agents (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.) or the like, which may be used in combination with an appropriate dissolution aid such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant (e.g., polysorbate 80TM and HCO-50), etc.
  • an oily medium for example, sesame oil, soybean oil or the like may be used, which can be used in combination with a dissolution aid such as benzyl benzoate, benzyl alcohol, etc.
  • the preventive/therapeutic agent described above may also be formulated with a buffer (e.g., phosphate buffer, sodium acetate buffer), a soothing agent (e.g., benzalkonium chloride, procaine hydrochloride, etc.), a stabilizer (e.g., human serum albumin, polyethylene glycol, etc.), a preservative (e.g., benzyl alcohol, phenol, etc.), an antioxidant, etc.
  • a buffer e.g., phosphate buffer, sodium acetate buffer
  • a soothing agent e.g., benzalkonium chloride, procaine hydrochloride, etc.
  • a stabilizer e.g., human serum albumin, polyethylene glycol, etc.
  • a preservative e.g., benzyl alcohol, phenol, etc.
  • an antioxidant e.g., benzyl alcohol, phenol, etc.
  • the preparation can be administered to human or mammal (e.g., rats, mice, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.).
  • human or mammal e.g., rats, mice, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.
  • the dose of the compound or its salt varies depending on the subject to be administered, target organ, conditions, method for administration, etc.; in oral administration for the patient (as 60 kg body weight) with, e.g., cancer, the dose of the compound or its salt that increases the expression level of GPR39 is normally about 0.1 mg to about 100 mg, preferably about 1.0 to about 50 mg, and more preferably about 1.0 to about 20 mg per day.
  • the single dose varies depending on the subject to be administered, target organ, conditions, method for administration, etc.
  • the compound or its salt intravenously to the patient with, e.g., cancer in a daily dose of about 0.01 to about 30 mg, preferably about 0.1 to about 20 mg, and more preferably about 0.1 to about 10 mg.
  • the corresponding dose as converted per 60 kg can be administered.
  • the antibody of the present invention is capable of specifically recognizing GPR39. Therefore, the antibody can be used to detect or neutralize GPR39 in a test fluid.
  • the present invention provides, for example, the following quantification methods:
  • a method for quantification of GPR39 in a test fluid which comprises reacting the test fluid with the antibody of the present invention immobilized on a carrier and a labeled form of the antibody of the present invention simultaneously or sequentially, and measuring the activity of the label on the immobilized carrier.
  • GPR39 can be assayed and in addition, can be detected by tissue staining or the like.
  • the antibody molecule itself may be used, or F(ab′) 2 , Fab′ or Fab fractions of the antibody molecule may also be used.
  • the quantification methods of GPR39 using the antibodies are not particularly limited. Any quantification method can be used, so long as the amount of antibody, antigen, or antibody-antigen complex corresponding to the amount of antigen (e.g., the amount of GPR39) in the test fluid can be detected by chemical or physical means and the amount of the antigen can be calculated from a standard curve prepared from standard solutions containing known amounts of the antigen. For example, nephrometry, competitive methods, immunometric method, and sandwich method are appropriately used, with the sandwich method described below being most preferable in terms of sensitivity and specificity.
  • the labeling agent for the methods using labeled substances there are employed, for example, radioisotopes, enzymes, fluorescent substances, luminescent substances, etc.
  • radioisotope for example, [ 125 I], [ 131 I], [ 3 H], [ 14 C] and the like are used.
  • enzyme described above stable enzymes with high specific activity are preferred; for example, ⁇ -galactosidase, ⁇ -glucosidase, alkaline phosphatase, peroxidase, malate dehydrogenase and the like are used.
  • the fluorescent substance used are fluorescamine and fluorescein isothiocyanate are used.
  • luminescent substance there are used, for example, luminol, luminol derivatives, luciferin, and lucigenin.
  • the biotin-avidin system may be used for binding antibody or antigen to the label.
  • insoluble polysaccharides such as agarose, dextran, cellulose, etc.
  • synthetic resin such as polystyrene, polyacrylamide, silicon, etc., and glass or the like are used.
  • the immobilized monoclonal antibody of the present invention is reacted with a test fluid (primary reaction), then with the labeled monoclonal antibody of the present invention (secondary reaction), and the activity of the label on the immobilizing carrier is measured, whereby the amount of GPR39 in the test fluid can be quantified.
  • the order of the primary and secondary reactions may be reversed, and the reactions may be performed simultaneously or with an interval.
  • the methods of labeling and immobilization can be performed by the methods described above.
  • the antibody used for immobilized or labeled antibodies is not necessarily one species, but a mixture of two or more species of antibody may be used to increase the measurement sensitivity.
  • antibodies that bind to different sites of GPR39 are preferably used as the monoclonal antibodies of the present invention for the primary and secondary reactions. That is, in the antibodies used for the primary and secondary reactions are, for example, when the antibody used in the secondary reaction recognizes the C-terminal region of GPR39, it is preferable to use the antibody recognizing the region other than the C-terminal region for the primary reaction, e.g., the antibody recognizing the N-terminal region.
  • the monoclonal antibodies of the present invention can be used for the assay systems other than the sandwich method, for example, competitive method, immunometric method, nephrometry, etc.
  • This reaction method includes a liquid phase method using a soluble antibody as an antibody, polyethylene glycol for B/F separation and a secondary antibody to the soluble antibody, and an immobilized method either using an immobilized antibody as the primary antibody, or using a soluble antibody as the primary antibody and immobilized antibody as the secondary antibody.
  • antigen in a test fluid and immobilized antigen are competitively reacted with a definite amount of labeled antibody, the immobilized phase is separated from the liquid phase, or antigen in a test fluid and an excess amount of labeled antibody are reacted, immobilized antigen is then added to bind the unreacted labeled antibody to the immobilized phase, and the immobilized phase is separated from the liquid phase. Then, the amount of the label in either phase is measured to quantify the antigen in the test fluid.
  • insoluble precipitate produced after the antigen-antibody reaction in gel or solution is quantified.
  • laser nephrometry using scattering of laser is advantageously employed.
  • GPR39 can be quantified with high sensitivity, using the antibody of the present invention.
  • the diseases associated with the dysfunction of GPR39 include metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc.
  • the diseases associated with the excessive action of GPR39 include, for example, excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria including interstitial cystitis, prostatic hyperplasia induced-pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms, various disorders caused by urinary calculus, etc., or inflammatory diseases (e.g., diabetic complications such as neuropathy, large vascular disorders, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases (e.g., asthma, atopic dermatitis or chronic obstructive pulmonary disease (COPD)), etc.
  • excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive
  • GPR39 is useful as a reagent for searching or determining the agonist (including a naturally occurring ligand, synthetic ligand and element) for GPR39 other than the metal elements described above, using the intracellular signal as an indicator.
  • the present invention provides a method of determining the agonist for GPR39, which comprises assaying the intracellular Ca 2+ level increasing activity or the IL-8 secretion promoting action mediated by GPR39, when a test compound or element or a salt thereof are brought in contact with a cell containing GPR39.
  • test compounds used include publicly known ligands (for example, angiotensin, bombesin, canavinoid, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide Y, opioids, purines, vasopressin, oxytocin, PACAP (e.g., PACAP27, PACAP38), secretin, glucagon, calcitonin, adrenomedulin, somatostatin, GHRH, CRF, ACTH, GRP, PTH, VIP (vasoactive intestinal and related polypeptide), somatostatin, dopamine, motilin, amylin, bradykinin, CGRP (calcitonin gene-related peptide), leukotrienes, pancreastatin, prostaglandins, thromboxane, adenosine, adrenaline, the chemokine superfamily (e.g., the CXC chemokine subfamily such as
  • salts with physiologically acceptable acids e.g., inorganic acids, etc.
  • bases e.g., organic acids, etc.
  • physiologically acceptable acid addition salts examples include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
  • organic acids e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic
  • test elements the elements described in, e.g., the Periodic Table, preferably, metal elements are used.
  • salts of the test elements include salts with acids such as hydrochloric acid, sulfuric acid, nitric acid, acetic acid, etc.
  • the compound e.g., a peptide, protein, non-peptide compound, synthetic compound or fermentation product, etc.
  • the compound or element or salts thereof that change the binding property or signal transduction of the metal element, which is a ligand, to GPR39 can be screened efficiently.
  • Examples of such a compound or element or a salt thereof include (a) a compound or element or a salt thereof showing the cell stimulating activities mediated by GPR39 (a so-called agonist for GPR39), (b) a compound or element or a salt thereof that inhibits the cell stimulating activities (a so-called antagonist to GPR39), (c) a compound or element or a salt thereof that potentiates the binding property of the metal element to GPR39, or (d) a compound or element or a salt thereof that decreases the binding property of the metal element to GPR39, and the like.
  • the present invention provides a method of screening a compound or element or a salt thereof or a salt thereof that changes the binding property or signal transduction of GPR39 to the metal element, which comprises comparing the following two cases: (i) the case wherein GPR39 is brought in contact with the metal element; and (ii) the case wherein GPR39 is brought in contact with the metal element and a test compound.
  • the method is characterized by assaying, e.g., the binding amount of the metal element to GPR39, the cell-stimulating activities, etc. in (i) and (ii) and comparing (i) and (ii).
  • the cell-stimulating activities include the activities that promote or suppress, for example, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release (increase in intracellular Ca 2+ level), intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential, phosphorylation of intracellular proteins, activation of c-fos, pH reduction, etc., an action of promoting the secretion of cytokines (e.g., IL-8) from the GPR39 expression cell UM-UC-3, etc.
  • the intracellular Ca 2+ level increasing activity, action of promoting the secretion of cytokines (e.g., IL-8) from the GPR39 expression cell UM-UC-3, etc. are preferred.
  • the present invention provides the following methods.
  • a method of screening a compound or element or a salt thereof that changes the binding property or signal transduction of a metal element to GPR39 which comprises measuring the binding amount of a radioisotope of the metal element to GPR39 in the case wherein the radioisotope of the metal element is brought in contact with GPR39 and in the case wherein the radioisotope of the metal element and a test compound or element or a salt thereof are brought in contact with GPR39, and comparing the cases.
  • a method of screening a compound or element or a salt thereof that changes the binding property or signal transduction of a metal element to GPR39 which comprises measuring the binding amount of a radioisotope of the metal element to a cell containing GPR39 or a membrane fraction of said cell, in the case wherein the radioisotope of the metal element is brought in contact with the cell containing GPR39 or a membrane fraction of said cell and in the case wherein the radioisotope of the metal element and a test compound or element or a salt thereof are brought in contact with the cell containing GPR39 or said membrane fraction, and comparing the cases.
  • a method of screening a compound or element or a salt thereof that changes the binding property or signal transduction of a metal element to GPR39 which comprises measuring the amount of a radioisotope of the metal element bound to GPR39, in the case wherein the radioisotope of the metal element is brought in contact with GPR39 expressed on a cell membrane by culturing a transformant containing the DNA of the present invention and in the case wherein the radioisotope of the metal element and a test compound or element or a salt thereof are brought in contact with GPR39 expressed on the cell membrane by culturing a transformant containing the DNA of the present invention, and comparing the cases.
  • a method of screening a compound or element or a salt thereof that changes the binding property or signal transduction of a metal element to GPR39 which comprises assaying GPR39-mediated cell stimulating activities in the case wherein a compound (e.g., a metal element or its radioisotope, etc.) that activates GPR39 is brought in contact with a cell containing GPR39 and in the case wherein a compound that activates GPR39 and a test compound or element or a salt thereof are brought in contact with the cell containing GPR39, and comparing the cell stimulating activities between the two cases.
  • a compound e.g., a metal element or its radioisotope, etc.
  • a method of screening a compound or element or a salt thereof that changes the binding property or signal transduction of a metal element to GPR39 which comprises assaying the receptor-mediated cell stimulating activities in the case wherein a compound (e.g., a metal element or its radioisotope, etc.) that activates GPR39 is brought in contact with GPR39 expressed on a cell membrane by culturing a transformant containing the DNA of the present invention and in the case wherein a compound that activates GPR39 and a test compound or element or a salt thereof are brought in contact with GPR39 expressed on a cell membrane by culturing a transformant containing the DNA of the present invention, and comparing the cell stimulating activities between the two cases.
  • a compound e.g., a metal element or its radioisotope, etc.
  • a compound or element or a salt thereof (a synthetic low molecular compound, especially a synthetic low molecular agonist) that changes the binding property of the metal element to GPR39 can be used as the ligand for GPR39 in place of the metal element described above.
  • the compound or element or a salt thereof that changes the binding property of the metal element to GPR39 can be obtained by performing the screening methods later described using, e.g., the metal element as a ligand.
  • the compound or element or a salt thereof that changes the binding property of the metal element to GPR39 is all merely referred to as the ligand.
  • GPR39 used for the screening method of the present invention may be any one, so long as it contains GPR39 described above, though GPR39-containing membrane fractions from mammalian organs are preferably employed. Since it is very difficult to obtain human-derived organs especially, human-derived GPR39, etc. expressed abundantly by use of recombinants are suitable for use in the screening.
  • the methods described above can be used and preferably, it is produced by expressing the DNA of the present invention expressed on mammalian cells or insect cells.
  • a complementary DNA may be used but is not limited thereto.
  • gene fragments or a synthetic DNA may also be used as the DNA fragment.
  • the DNA fragment is preferably incorporated into a polyhedron promoter of nuclear polyhedrosis virus (NPV) belonging to the Baculovirus, an SV40-derived promoter, a promoter of retrovirus, a metallothionein promoter, a human heat shock promoter, a cytomegalovirus promoter, SR ⁇ promoter, etc. at the downstream thereof.
  • NDV nuclear polyhedrosis virus
  • the quantity and quality of the thus expressed receptors can be examined by a publicly known method, for example, by the method described in the literature [Nambi, P. et al., J. Biol. Chem., 267, 19555-19559, 1992].
  • the substance containing GPR39 may be GPR39 purified by publicly known methods, or a cell containing said GPR39 or a membrane fraction of the cell containing said GPR39 may be used as well.
  • the cell may be fixed with glutaraldehyde, formalin, etc.
  • the fixation may be carried out by a publicly known method.
  • the cell containing GPR39 refers to a host cell expressing the GPR39.
  • Examples of such a host cell include Escherichia coli, Bacillus subtilis , yeast, insect cells, animal cells, etc.
  • the cell membrane fraction refers to a fraction abundant in cell membrane obtained by cell disruption and subsequent fractionation by publicly known methods.
  • Cell disruption methods include cell squashing using a Potter-Elvehjem homogenizer, disruption using a Waring blender or Polytron (manufactured by Kinematica Inc.), disruption by ultrasonication, disruption by cell spraying through thin nozzles under an increased pressure using a French press, or the like.
  • Cell membrane fractionation is effected mainly by fractionation using a centrifugal force, such as centrifugation for fractionation and density gradient centrifugation.
  • cell disruption fluid is centrifuged at a low speed (500 rpm to 3,000 rpm) for a short period of time (normally about 1 to about 10 minutes), the resulting supernatant is then centrifuged at a higher speed (15,000 rpm to 30,000 rpm) normally for 30 minutes to 2 hours.
  • the precipitate thus obtained is used as the membrane fraction.
  • the membrane fraction is abundant in GPR39 expressed and membrane components such as cell-derived phospholipids, membrane proteins, etc.
  • the amount of GPR39 in the GPR39-containing cell or membrane fraction is preferably 10 3 to 10 8 molecules per cell, more preferably 10 5 to 10 7 molecules per cell.
  • the ligand binding activity per unit of membrane fraction increases so that not only the highly sensitive screening system can be constructed but also large quantities of samples can be assayed with the same lot.
  • the GPR39 fraction is preferably a fraction of naturally occurring type GPR39 or a fraction of recombinant GPR39 having an activity equivalent thereto.
  • the equivalent activity is intended to mean the ligand binding activity or the signal transduction activity, which is equivalent to the activity possessed by naturally occurring type GPR39.
  • radioisotopes of the ionizable metal element such as cadmium, zinc, copper, nickel, etc. are employed.
  • zinc 65 ( 65 Zn), nickel 63 ( 63 Ni), etc. are used.
  • nickel 63 ( 63 Ni) is preferred.
  • a GPR39 preparation is prepared by suspending a cell containing GPR39 or a membrane fraction of the cell in a buffer appropriate for use in the screening method. Any buffer can be used so long as it does not interfere the ligand-GPR39 binding, including a phosphate buffer or a Tris-HCl buffer, having pH of 4 to 10 (preferably pH of 6 to 8), etc.
  • a surfactant such as CHAPS, Tween-80TM (Kao-Atlas Inc.), digitonin, deoxycholate, etc.
  • CHAPS CHAPS
  • Tween-80TM Kao-Atlas Inc.
  • digitonin deoxycholate
  • deoxycholate deoxycholate
  • a protease inhibitor such as PMSF, leupeptin, E-64 (manufactured by Peptide Institute, Inc.), pepstatin, etc. may also be added.
  • a given amount (5,000 cpm to 500,000 cpm) of the labeled ligand is added to 0.01 ml to 10 ml of the receptor solution, in which 10 4 M to 10 ⁇ 10 M of a test compound is co-present.
  • a reaction tube containing an unlabeled ligand in a large excess is also provided. The reaction is carried out at approximately 0° C. to 50° C., preferably approximately 4° C. to 37° C. for about 20 minutes to about 24 hours, preferably about 30 minutes to 3 hours. After completion of the reaction, the reaction mixture is filtrated through glass fiber filter paper, etc. and washed with an appropriate volume of the same buffer.
  • the residual radioactivity on the glass fiber filter paper is then measured by means of a liquid scintillation counter or ⁇ -counter.
  • the test compound showing the specific binding amount (B minus NSB) of, e.g., 50% or less may be selected as a candidate compound.
  • the method d) or e) described above for screening the compound or element or a salt thereof that changes the binding property or signal transduction of the ligand to GPR39 or signal transduction can be performed as follows.
  • GPR39-mediated cell stimulating activities can be determined by a publicly known method, or using an assay kit commercially available.
  • the cells containing GPR39 are first cultured in a multiwell plate, etc. Prior to screening, the medium is replaced with fresh medium or with an appropriate non-cytotoxic buffer, followed by incubation for a given period of time in the presence of a test compound, etc. Subsequently, the cells are extracted or the supernatant is recovered and the resulting product is quantified by appropriate procedures. Where it is difficult to detect the production of the cell-stimulating activity indicator (e.g., cAMP, arachidonic acid, etc.) due to a degrading enzyme contained in the cells, an inhibitor against such as a degrading enzyme may be added prior to the assay. For detecting the activities such as the cAMP production suppression activity, the baseline production in the cells is increased by forskolin or the like and the suppressing effect on the increased baseline production can be detected.
  • the cell-stimulating activity indicator e.g., cAMP, arachidonic acid, etc.
  • an inhibitor against such as a degrading enzyme may be added prior to
  • cells for screening through the assay for the cell stimulating activities, cells, in which an appropriate GPR39 has been expressed, are necessary.
  • Preferred cells, in which GPR39 has been expressed are a naturally occurring type cell line containing GPR39 and the aforesaid cell line, in which recombinant type GPR39 has been expressed.
  • test compounds examples include peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, blood plasma, etc. These test compounds may be either novel or publicly known compounds.
  • salts with physiologically acceptable acids e.g., inorganic acids, etc.
  • bases e.g., organic acids, etc.
  • physiologically acceptable acid addition salts examples include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
  • organic acids e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic
  • test elements the elements described in, e.g., the Periodic Table, are used. Among them, metal elements are preferred.
  • Salts of the test elements include, for example, salts with acids such as hydrochloric acid, sulfuric acid, nitric acid, acetic acid, etc.
  • the test compound which is preferably used is a compound designed to bind to the ligand-binding pocket, based on the atomic coordinate and the position of the ligand-binding pocket in the active site of GPR39.
  • the atomic coordinate and the position of the ligand-binding pocket in the active site of GPR39 can be determined by publicly known methods or modifications thereof.
  • the compound that changes the binding property of the ligand to GPR39 is either an agonist or an antagonist.
  • the confirmation can be made by (i) or (ii) below.
  • the compound that changes the binding property of the metal element to GPR39 (especially inhibits the binding) is obtained. It is then determined whether or not the compound possesses the cell stimulating activity described above. When the compound or its salt has the cell stimulating activity, it is an agonist for GPR39, whereas the compound or its salt having no cell stimulating activity is an antagonist to GPR39.
  • test compound is brought in contact with a cell containing GPR39 to assay the cell stimulating activity described above.
  • the test compound or its salt having the cell stimulating activity is an agonist for GPR39.
  • the cell stimulating activity is assayed in the case wherein a compound that activates GPR39 (e.g., a metal element) is brought in contact with a cell containing GPR39 and in the case wherein a compound that activates GPR39 and a test compound are brought in contact with a cell containing GPR39, and comparison is made therebetween.
  • the test compound which can decrease the cell stimulating activity mediated by the compound or its salt that activates GPR39, is an antagonist to GPR39.
  • the kit for screening the compound or its salt that changes the binding property or signal transduction of the ligand to GPR39 is a kit comprising GPR39, a cell containing GPR39, or a membrane fraction of the cell containing GPR39, and the like.
  • Examples of the screening kit of the present invention include the following.
  • the solution is sterilized by filtration through a 0.45 ⁇ m filter, and stored at 4° C. or may be prepared at use.
  • CHO cells wherein GPR39 has been expressed are passaged in a 12-well plate at a density of 5 ⁇ 10 5 cells/well followed by culturing at 37° C. under 5% CO 2 and 95% air for 2 days.
  • a radioisotope such as zinc 65 ( 65 Zn), nickel 63 ( 63 Ni), etc.
  • An aqueous solution is stored at 4° C. or ⁇ 20° C. and diluted to 1 ⁇ M with the assay buffer upon use.
  • the ligand is dissolved in and adjusted to 1 mM with PBS containing 0.1% bovine serum albumin (manufactured by Sigma, Inc.) and stored at ⁇ 20° C.
  • CHO cells wherein GPR39 has been expressed are cultured in a 12-well culture plate and washed twice with 1 ml of the assay buffer, and 490 ⁇ l of the assay buffer is added to each well.
  • the compound or element or a salt thereof which is obtained by using the screening method or the screening kit of the present invention, is the compound or element or a salt thereof, which has the action of changing the binding property or signal transduction of the metal element to GPR39 or signal transduction.
  • the compound is: (a) a compound or element or a salt thereof having the cell-stimulating activity mediated by GPR39 (a so-called agonist for GPR39); (b) a compound or element or a salt thereof having no cell stimulating activity (a so-called antagonist to GPR39); (c) a compound or element or a salt thereof that potentiates the binding affinity of the metal element to GPR39; or (d) a compound or element or a salt thereof that reduces the binding affinity of the metal element to GPR39.
  • the compounds obtained by using screening method of the present invention include peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, etc. These compounds may be novel or known compounds.
  • salts with physiologically acceptable acids e.g., inorganic acids, etc.
  • bases e.g., organic acids, etc.
  • physiologically acceptable acid addition salts examples include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
  • organic acids e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic
  • the elements obtained by the screening method or screening kit of the present invention for example, the elements described in, e.g., the Periodic Table, are used. Among them, metal elements are preferred.
  • the salts of the elements include, for example, salts with acid such as hydrochloric acid, sulfuric acid, nitric acid, acetic acid, etc.
  • the agonists for GPR39 have the same physiological activities as those of the metal element, which is a ligand for GPR39, the agonists are useful as safe and low toxic pharmaceuticals, correspondingly to the physiological activity possessed by the metal element.
  • the antagonists to GPR39 can suppress the physiological activities possessed by the metal element, which is a ligand for GPR39, the antagonists are useful as safe and low toxic pharmaceuticals to suppress the physiological activities of the metal element.
  • the compound or element or a salt thereof that potentiates the binding affinity of the metal element to GPR39 can potentiate the physiological activity the metal element has, and is thus useful as a safe and low toxic pharmaceutical correspondingly to the physiological activity possessed by the metal element.
  • the compound or element or a salt thereof that reduces the binding affinity of the metal element to GPR39, element or its salt can reduce the physiological activities the metal element has, and is useful as a safe and low toxic pharmaceutical to suppress the physiological activity possessed by the metal element.
  • the agonist for GPR39 or the compound or element or a salt thereof that potentiates the binding affinity of the metal element to GPR39 is useful as a prophylactic/therapeutic agent for diseases, for example, metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc., or as an agent for promoting the diseases,
  • the antagonist to GPR39 or the compound or element or a salt thereof that reduces the binding affinity of the metal element to GPR39 is useful as a prophylactic/therapeutic agent for diseases, for example, excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria including interstitial cystitis, prostatic hyperplasia induced-pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms, various disorders caused by urinary calculus, etc., an agent for suppressing the secretion of cytokines (e.g., IL-8), or a prophylactic/therapeutic agent for inflammatory diseases (e.g., diabetic complications such as neuropathy, large vascular disorders, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralg
  • diseases for
  • the compound or element or a salt thereof which is obtained by the screening method of the present invention, is used as a pharmaceutical composition above, the compound or element or a salt thereof can be prepared into a pharmaceutical preparation in a conventional manner.
  • the compound or its salt can be used orally in the form of tablets which may be tablets, if necessary, coated with sugar, capsules, elixirs, microcapsules, etc., or parenterally in the form of injectable preparations such as a sterile solution or a suspension in water or with other pharmaceutically acceptable liquid.
  • injectable preparations such as a sterile solution or a suspension in water or with other pharmaceutically acceptable liquid.
  • These preparations can be manufactured, e.g., by mixing the compound, with a physiologically acceptable known carrier, flavoring agent, excipient, vehicle, antiseptic, stabilizer, binder, etc., in a unit dosage form required in a generally accepted manner applied to making pharmaceutical preparations.
  • the active ingredient in the preparation is controlled in such an amount that an appropriate dose is obtained within the specified range given.
  • Additives miscible with tablets, capsules, etc. include a binder such as gelatin, corn starch, tragacanth or gum arabic, an excipient such as crystalline cellulose, a puffiness agent such as corn starch, gelatin, alginic acid, etc., a lubricant such as magnesium stearate, a sweetening agent such as sucrose, lactose or saccharin, a flavoring agent such as peppermint, akamono oil or cherry, and the like.
  • a binder such as gelatin, corn starch, tragacanth or gum arabic
  • an excipient such as crystalline cellulose
  • a puffiness agent such as corn starch, gelatin, alginic acid, etc.
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin
  • a flavoring agent such as peppermint, akamono oil or cherry, and the like.
  • liquid carriers
  • a sterile composition for injection may be formulated following a conventional manner used to make pharmaceutical compositions, e.g., by dissolving or suspending the active ingredients in a vehicle such as water for injection with a naturally occurring vegetable oil such as sesame oil, coconut oil, etc. to prepare the pharmaceutical composition.
  • an aqueous medium for injection examples include physiological saline, an isotonic solution containing glucose and other auxiliary agents (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.) or the like, which may be used in combination with an appropriate dissolution aid such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant (e.g., polysorbate 80TM and HCO-50), etc.
  • an oily medium for example, sesame oil, soybean oil or the like may be used, and may be used in combination with a dissolution aid such as benzyl benzoate, benzyl alcohol, etc.
  • the preventive/therapeutic agent described above may also be formulated with a buffer (e.g., phosphate buffer, sodium acetate buffer), a soothing agent (e.g., benzalkonium chloride, procaine hydrochloride, etc.), a stabilizer (e.g., human serum albumin, polyethylene glycol, etc.), a preservative (e.g., benzyl alcohol, phenol, etc.), an antioxidant, etc.
  • a buffer e.g., phosphate buffer, sodium acetate buffer
  • a soothing agent e.g., benzalkonium chloride, procaine hydrochloride, etc.
  • a stabilizer e.g., human serum albumin, polyethylene glycol, etc.
  • a preservative e.g., benzyl alcohol, phenol, etc.
  • an antioxidant e.g., benzyl alcohol, phenol, etc.
  • the preparation can be administered to human or mammal (e.g., rats, mice, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.).
  • human or mammal e.g., rats, mice, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.
  • the dose of the compound or element or a salt thereof varies depending on subject to be administered, target organ, conditions, method for administration, etc.; in oral administration, the agonist for GPR39 is administered to the patient (as 60 kg body weight) with, e.g., cancer normally in a dose of about 0.1 mg to about 100 mg, preferably about 1.0 to about 50 mg, and more preferably about 1.0 to about 20 mg per day.
  • the single dose may vary depending on subject to be administered, target organ, conditions, method for administration, etc.
  • the agonist for GPR39 is advantageously administered intravenously to the patient (as 60 kg body weight) with, e.g., cancer in a daily dose of about 0.01 to about 30 mg, preferably about 0.1 to about 20 mg, and more preferably about 0.1 to about 10 mg.
  • the corresponding dose as converted per 60 kg can be administered.
  • the present invention provides the following methods.
  • a method for confirming that a preventive/therapeutic drug for metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc.; excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystit
  • a method for confirming that a preventive/therapeutic drug for metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc., or a drug for promoting the secretion of cytokines (e.g., IL-8) is an agonist for GPR39, which comprises using GPR39.
  • a preventive/therapeutic drug for excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria including interstitial cystitis, prostatic hyperplasia induced-pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms, various disorders caused by urinary calculus, etc., a drug for suppressing the secretion of cytokines (e.g., IL-8), or a preventive/therapeutic drug for inflammatory diseases (e.g., diabetic complications such as neuropathy, large vascular disorders, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases (e.g., asthma, atopic dermatitis or chronic obstructive pulmonary disease (COPD)), etc.
  • cytokines
  • This confirmation method can be performed by using the drug described above in place of the test compound in the above methods of screening the compound that changes the binding property of the metal element to GPR39.
  • the antibody of the present invention is capable of specifically recognizing GPR39 and can be used for screening the compound or its salt that changes the amount of GPR39 in the cell membrane.
  • the present invention provides, for example, the following methods:
  • a method of screening the compound or its salt that changes the amount of GPR39 in the cell membrane which comprises preparing a slice of a) blood, b) particular organs or c) tissues, cells, etc. isolated from organs of non-human mammals and quantifying the stained receptor protein on the cell surface using immunostaining assay thereby to confirm the protein on the cell membrane.
  • the present invention provides:
  • a method of screening the compound or its salt that changes the amount of GPR39 in the cell membrane which comprises preparing a slice of a transformant expressing GPR39 and quantifying the stained receptor protein on the cell surface using immunostaining assay thereby to confirm the protein on the cell membrane.
  • the GPR39 contained in the cell membrane fraction can be measured as follows.
  • mice, rats, rabbits, sheep, swine, bovine, cats, dogs, monkeys, more specifically, rats, mice or rabbits with immunodeficiency, etc. receive a drug (e.g., an immunomodulator, etc.) or physical stress (e.g., soaking stress, electric shock, light and darkness, low temperature, etc.), and the blood, particular organs (e.g., brain, liver, kidney, etc.), or tissues or cells isolated from the organs are obtained after a specified period of time.
  • a drug e.g., an immunomodulator, etc.
  • physical stress e.g., soaking stress, electric shock, light and darkness, low temperature, etc.
  • the obtained organs, tissues, cells or the like are suspended in, for example, an appropriate buffer (e.g., Tris hydrochloride buffer, phosphate buffer, HEPES buffer, etc.), and the organs, tissues or cells are disrupted, and the cell membrane fraction is obtained using surfactants (e.g., Triton-X 100TM, Tween 20TM) and further using techniques such as centrifugal separation, filtration, column fractionation, etc.
  • an appropriate buffer e.g., Tris hydrochloride buffer, phosphate buffer, HEPES buffer, etc.
  • surfactants e.g., Triton-X 100TM, Tween 20TM
  • the cell membrane fraction refers to a fraction abundant in cell membrane obtained by cell disruption and subsequent fractionation by publicly known methods.
  • Cell disruption methods include cell squashing using a Potter-Elvehjem homogenizer, disruption using a Waring blender or Polytron (manufactured by Kinematica Inc.), disruption by ultrasonication, disruption by cell spraying through thin nozzles under an increased pressure using a French press, or the like.
  • Cell membrane fractionation is effected mainly by fractionation using a centrifugal force, such as centrifugation for fractionation and density gradient centrifugation.
  • cell disruption fluid is centrifuged at a low speed (500 rpm to 3,000 rpm) for a short period of time (normally about 1 to about 10 minutes), the resulting supernatant is then centrifuged at a higher speed (15,000 rpm to 30,000 rpm) normally for 30 minutes to 2 hours.
  • the precipitate thus obtained is used as the membrane fraction.
  • the membrane fraction is abundant in GPR39 expressed and membrane components such as cell-derived phospholipids, membrane proteins, etc.
  • the GPR39 contained in the cell membrane fraction can be quantified by, for example, the sandwich immunoassay, western blot analysis, etc. using the antibody of the present invention.
  • the sandwich immunoassay can be performed as described above, and the western blotting can be performed by publicly known methods.
  • Transformants expressing GPR39 are prepared by the method described above, and the GPR39 contained in the cell membrane fraction can be quantified.
  • the compound or its salt that changes the amount of GPR39 in cell membranes can be screened as follows.
  • Normal non-human mammal or disease model of non-human mammal is administered with a test compound at a specified period of time before (30 minutes to 24 hours before, preferably 30 minutes to 12 hours before, more preferably 1 hour to 6 hours before), at a specified time after (30 minutes to 3 days after, preferably 1 hour to 2 days after, more preferably 1 hour to 24 hours after), or simultaneously with a drug or physical stress.
  • a specified time 30 minute to 3 days, preferably 1 hour to 2 days, more preferably 1 hour to 24 hours
  • the amount of GPR39 in the cell membranes can be quantified.
  • Transformants are cultured in a conventional manner and a test compound is mixed in the culture medium. After a specified time (after 1 day to 7 days, preferably after 1 day to 3 days, more preferably after 2 to 3 days), the amount of GPR39 in the cell membranes can be quantified.
  • the GPR39 contained in cell membrane fractions is confirmed as follows.
  • non-human mammals or disease models of non-human mammals e.g., mice, rats, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc., more specifically, immunodeficiency model rats, mice, rabbits, etc.
  • drugs e.g., an immunomodulator, etc.
  • physical stress e.g., soaking stress, electric shock, light and darkness, low temperature, etc.
  • blood or particular organ e.g., brain, liver, kidney, etc.
  • Tissue sections are prepared from the thus obtained organs, tissues, cells, etc.
  • the staining intensity of the receptor protein on the cell surface is quantified to confirm the protein on the cell membrane, whereby the amount of GPR39 on the cell membrane can be confirmed quantitatively or qualitatively.
  • salts with physiologically acceptable acids e.g., inorganic acids, etc.
  • bases e.g., organic acids, etc.
  • physiologically acceptable acid addition salts examples include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
  • organic acids e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic
  • the compound or its salts obtained by the screening method of the present invention are the compound or its salts that have the action of changing the amount of GPR39 in cell membranes.
  • these compounds are: (a) a compound or its salts that increase the amount of GPR39 in cell membranes thereby to potentiate the G protein-coupled receptor-mediated cell-stimulating activities; and (b) a compound or its salts that decrease the amount of GPR39 in cell membranes thereby to attenuate the cell stimulating-activity.
  • the compounds may be peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, and these compounds may be novel or publicly known compounds.
  • salts with physiologically acceptable acids e.g., inorganic acids, etc.
  • bases e.g., organic acids, etc.
  • physiologically acceptable acid addition salts examples include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
  • organic acids e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic
  • the compound or its salts that increase the amount of GPR39 in cell membranes thereby to potentiate the cell-stimulating activity are useful as safe and low toxic preventive/therapeutic agents for diseases associated with the dysfunction of GPR39.
  • the compound or its salt that decreases the expression level of GPR39 in cell membranes thereby to attenuate the cell stimulating activity is useful as a safe and low toxic agent for preventing/treating diseases caused by the overexpression of GPR39.
  • the compound or its salt that increases the amount of GPR39 in cell membranes can be used as a prophylactic/therapeutic agent for diseases, e.g., metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc., or an agent for promoting the secretion of cytokines (e.g., metal
  • the compound or its salt that decreases the amount of GPR39 in cell membranes can be used as a prophylactic/therapeutic agent for diseases, e.g., excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria including interstitial cystitis, prostatic hyperplasia induced-pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms, various disorders caused by urinary calculus, etc., an agent for suppressing the secretion of cytokines (e.g., IL-8), or a prophylactic/therapeutic agent for inflammatory diseases (e.g., diabetic complications such as neuropathy, large vascular disorders, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases (e.
  • diseases
  • the compound or its salt which is obtained by using the screening method of the present invention, is used as the pharmaceutical composition above, the compound or its salt can be prepared into a pharmaceutical preparation in a conventional manner.
  • the compound can be used orally in the form of tablets which may be tablets, if necessary, coated with sugar, capsules, elixirs, microcapsules, etc., or parenterally in the form of injectable preparations such as a sterile solution or a suspension in water or with other pharmaceutically acceptable liquid.
  • injectable preparations such as a sterile solution or a suspension in water or with other pharmaceutically acceptable liquid.
  • These preparations can be manufactured, e.g., by mixing the compound, with a physiologically acceptable known carrier, flavoring agent, excipient, vehicle, antiseptic, stabilizer, binder, etc., in a unit dosage form required in a generally accepted manner applied to making pharmaceutical preparations.
  • the active ingredient in the preparation is controlled in such an amount that an appropriate dose is obtained within the specified range given.
  • Additives miscible with tablets, capsules, etc. include a binder such as gelatin, corn starch, tragacanth or gum arabic, an excipient such as crystalline cellulose, a puffiness agent such as corn starch, gelatin, alginic acid, etc., a lubricant such as magnesium stearate, a sweetening agent such as sucrose, lactose or saccharin, a flavoring agent such as peppermint, akamono oil or cherry, and the like.
  • a binder such as gelatin, corn starch, tragacanth or gum arabic
  • an excipient such as crystalline cellulose
  • a puffiness agent such as corn starch, gelatin, alginic acid, etc.
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin
  • a flavoring agent such as peppermint, akamono oil or cherry, and the like.
  • liquid carriers
  • a sterile composition for injection may be formulated following a conventional manner used to make pharmaceutical compositions, e.g., by dissolving or suspending the active ingredients in a vehicle such as water for injection with a naturally occurring vegetable oil such as sesame oil, coconut oil, etc. to prepare the pharmaceutical composition.
  • an aqueous medium for injection examples include physiological saline, an isotonic solution containing glucose and other auxiliary agents (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.) or the like, which may be used in combination with an appropriate dissolution aid such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant (e.g., polysorbate 80TM and HCO-50), etc.
  • an oily medium for example, sesame oil, soybean oil or the like may be used, which can be used in combination with a dissolution aid such as benzyl benzoate, benzyl alcohol, etc.
  • the preventive/therapeutic agent described above may also be formulated with a buffer (e.g., phosphate buffer, sodium acetate buffer), a soothing agent (e.g., benzalkonium chloride, procaine hydrochloride, etc.), a stabilizer (e.g., human serum albumin, polyethylene glycol, etc.), a preservative (e.g., benzyl alcohol, phenol, etc.), an antioxidant, etc.
  • a buffer e.g., phosphate buffer, sodium acetate buffer
  • a soothing agent e.g., benzalkonium chloride, procaine hydrochloride, etc.
  • a stabilizer e.g., human serum albumin, polyethylene glycol, etc.
  • a preservative e.g., benzyl alcohol, phenol, etc.
  • an antioxidant e.g., benzyl alcohol, phenol, etc.
  • the preparation can be administered to human or mammals (e.g., rats, mice, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.).
  • human or mammals e.g., rats, mice, rabbits, sheep, swine, bovine, cats, dogs, monkeys, etc.
  • the dose of the compound or its salts varies depending on subject to be administered, target organ, conditions, methods for administration, etc.; in oral administration, the compound or its salt that increases the amount of GPR39 in cell membranes is administered to the patient (as 60 kg body weight) with, e.g., cancer normally in a dose of about 0.1 mg to about 100 mg, preferably about 1.0 to about 50 mg, and more preferably about 1.0 to about 20 mg per day.
  • the single dose may vary depending on subject to be administered, target organ, conditions, methods for administration, etc.
  • the compound or its salt that increases the amount of GPR39 in cell membranes is advantageously administered intravenously to the patient (as 60 kg body weight) with, e.g., cancer in a daily dose of about 0.01 to about 30 mg, preferably about 0.1 to about 20 mg, and more preferably about 0.1 to about 10 mg.
  • the corresponding dose as converted per 60 kg can be administered.
  • the neutralizing activity of the antibody to GPR39 means the activity of inactivating the signal transduction function in which GPR39 takes part.
  • the antibody can inactivate signal transduction in which GPR39 takes part, for example, the GPR39-mediated cell stimulating activities (e.g., the activities that promote or inhibit arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, changes in cell membrane potential, phosphorylation of intracellular proteins, activation of c-fos, pH reduction, etc.; an action of promoting the secretion of cytokines (e.g., IL-8) etc., in particular, intracellular Ca 2+ level increasing activity (intracellular Ca 2+ release activity), an action of promoting the secretion of cytokines (e.g., IL-8)).
  • the GPR39-mediated cell stimulating activities e.g., the activities that promote or inhibit arachidonic
  • the antibody to GPR39 can be used as a prophylactic/therapeutic agent for diseases caused by the excessive action of GPR39 or abundance of the metal element, for example, excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria including interstitial cystitis, prostatic hyperplasia induced-pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms, various disorders caused by urinary calculus, etc., an agent for suppressing the secretion of cytokines (e.g., IL-8), or a prophylactic/therapeutic agent for inflammatory diseases (e.g., diabetic complications such as neuropathy, large vascular disorders, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neural
  • cytokines e.g.,
  • the preventive/therapeutic agent described above can be prepared in the same manner as in the aforesaid pharmaceutical composition comprising the GPR39 or the antagonist to the GPR39 and provided for use.
  • the antisense DNA of the present invention can be used as a prophylactic/therapeutic agent for diseases caused by the excessive action of GPR39, abundance of the metal element or the like, for example, excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria including interstitial cystitis, prostatic hyperplasia induced-pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms, various disorders caused by urinary calculus, etc., an agent for suppressing the secretion of cytokines (e.g., IL-8), or a prophylactic/therapeutic agent for inflammatory diseases (e.g., diabetic complications such as neuropathy, large vascular disorders, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases (
  • the antisense DNA itself is administered; alternatively, the antisense DNA is inserted into an appropriate vector such as retrovirus vector, adenovirus vector, adenovirus-associated virus vector, etc. and then administered in a conventional manner.
  • the antisense DNA may also be administered as naked, or with adjuvants to assist its uptake by gene gun or through a catheter such as a catheter with a hydrogel.
  • the antisense DNA may also be used as an oligonucleotide probe for diagnosis to investigate the presence of the DNA of the present invention or the state of its expression in tissues or cells.
  • the present invention provides a non-human mammal bearing DNA which is exogenous (hereinafter briefly referred to as the exogenous DNA of the present invention) or its variant DNA (sometimes briefly referred to as the exogenous variant DNA of the present invention).
  • the present invention provides:
  • the non-human mammal bearing the exogenous DNA of the present invention or its variant DNA can be produced by transferring a desired DNA into an unfertilized egg, a fertilized egg, a spermatozoon, a germinal cell containing a primordial germinal cell thereof, or the like, preferably in the embryogenic stage in the development of a non-human mammal (more preferably in the single cell or fertilized cell stage and generally before the 8-cell phase), by standard means, such as the calcium phosphate method, the electric pulse method, the lipofection method, the agglutination method, the microinjection method, the particle gun method, the DEAE-dextran method, etc.
  • standard means such as the calcium phosphate method, the electric pulse method, the lipofection method, the agglutination method, the microinjection method, the particle gun method, the DEAE-dextran method, etc.
  • the exogenous DNA of the present invention into a somatic cell, a living organ, a tissue cell, or the like by the DNA transfer, and utilize the transformant for cell culture, tissue culture, etc.
  • these cells may be fused with the above-described germinal cell by a publicly known cell fusion method to prepare the DNA transgenic animal of the present invention.
  • mice examples include bovine, swine, sheep, goat, rabbits, dogs, cats, guinea pigs, hamsters, mice, rats, etc.
  • rodents especially mice (e.g., C57Bl/16 strain, DBA2 strain, etc. for a pure line and for a cross line, B6C3F 1 strain, BDF 1 strain B6D2F 1 strain, BALB/c strain, ICR strain, etc.), rats (Wistar, SD, etc.) or the like, since they are relatively short in ontogeny and life cycle from a standpoint of producing model animals for human disease.
  • “Mammal” in a recombinant vector that can be expressed in the mammals includes the aforesaid non-human mammal and human.
  • the exogenous DNA of the present invention refers to the DNA of the present invention that is once isolated and extracted from mammal, not the DNA of the present invention inherently possessed by the non-human mammal.
  • the mutant DNA of the present invention includes mutants resulting from variation (e.g., mutation, etc.) in the base sequence of the original DNA of the present invention, specifically DNAs resulting from base addition, deletion, substitution with other bases, etc. and further including abnormal DNA.
  • variation e.g., mutation, etc.
  • the abnormal DNA is intended to mean DNA that expresses the abnormal GPR39 and exemplified by the DNA that expresses GPR39 for suppressing the function of normal GPR39.
  • the exogenous DNA of the present invention may be any one of those derived from a mammal of the same species as, or a different species from, the mammal as the target animal.
  • a DNA transgenic mammal that expresses the DNA of the present invention to a high level can be prepared by microinjecting a DNA construct (e.g., vector, etc.) ligated with the human DNA of the present invention into a fertilized egg of the target non-human mammal downstream various promoters which are capable of expressing the DNA derived from various mammals (e.g., rabbits, dogs, cats, guinea pigs, hamsters, rats, mice, etc.) bearing the DNA of the present invention highly homologous to the human DNA.
  • a DNA construct e.g., vector, etc.
  • various promoters which are capable of expressing the DNA derived from various mammals (e.g., rabbits, dogs, cats, guinea pigs, hamsters, rats, mice, etc.) bearing the DNA of the present invention highly homologous to the human DNA.
  • Escherichia coli - derived plasmids there are Escherichia coli - derived plasmids, Bacillus subtilis - derived plasmids, yeast-derived plasmids, bacteriophages such as ⁇ phage, retroviruses such as Moloney leukemia virus, etc., and animal viruses such as vaccinia virus, baculovirus, etc.
  • Escherichia coli - derived plasmids, Bacillus subtilis - derived plasmids, or yeast-derived plasmids, etc. are preferably used.
  • promoters for regulating the DNA expression include (i) promoters for DNA derived from viruses (e.g., simian virus, cytomegalovirus, Moloney leukemia virus, JC virus, breast cancer virus, poliovirus, etc.) and (ii) promoters derived from various mammals (human, rabbits, dogs, cats, guinea pigs, hamsters, rats, mice, etc.), for example, promoters of albumin, insulin II, uroplakin II, elastase, erythropoietin, endothelin, muscular creatine kinase, glial fibrillary acidic protein, glutathione S-transferase, platelet-derived growth factor ⁇ , keratins K1, K10 and K14, collagen types I and II, cyclic AMP-dependent protein kinase ⁇ I subunit, dystrophin, tartarate-resistant alkaline phosphatase, atrial na
  • MHC class I antigen H-2L
  • H-ras H-ras
  • renin dopamine ⁇ -hydroxylase
  • TPO thyroid peroxidase
  • protein chain elongation factor 1 ⁇ EF-1 ⁇
  • ⁇ actin ⁇ and ⁇ myosin heavy chains
  • myosin light chains 1 and 2
  • myelin base protein thyroglobulins.
  • Thy-1 immunoglobulins
  • H-chain variable region (VNP) serum amyloid component P
  • myoglobin troponin C
  • smooth muscle ⁇ actin smooth muscle ⁇ actin
  • preproencephalin A vasopressin, etc.
  • cytomegalovirus promoters human protein elongation factor 1 ⁇ (EF-1 ⁇ ) promoters
  • human and fowl ⁇ actin promoters etc., which are capable of high expression in the whole body are preferred.
  • the vectors described above have a sequence that terminates the transcription of the desired messenger RNA in the DNA transgenic animal (generally termed a terminator); for example, a sequence of each DNA derived from viruses and various mammals, and SV40 terminator of the simian virus and the like are preferably used.
  • a terminator for example, a sequence of each DNA derived from viruses and various mammals, and SV40 terminator of the simian virus and the like are preferably used.
  • a splicing signal, an enhancer region, a portion of the intron of eukaryotic DNA, etc. for each DNA can be ligated at the 5′ upstream of a promoter region, between the promoter region and a translation region, or at the 3′ downstream of the translation region, depending upon the purpose.
  • the translational region for normal GPR39 can be obtained using as a starting material the entire genomic DNA or its portion of liver, kidney, thyroid cell or fibroblast origin from human or various mammals (e.g., rabbits, dogs, cats, guinea pigs, hamsters, rats, mice, etc.) or various commercially available genomic DNA libraries, or using cDNA prepared by a publicly known method from RNA of liver, kidney, thyroid cell or fibroblast origin as a starting material.
  • an exogenous abnormal DNA can produce the translational region through variation of the translational region of normal GPR39 obtained from the cells or tissues described above by point mutagenesis.
  • the translational region can be prepared by a conventional DNA engineering technique, in which the DNA is ligated downstream the aforesaid promoter and if desired, upstream the translation termination site, as a DNA construct capable of being expressed in the transgenic animal.
  • the exogenous DNA of the present invention is transferred at the fertilized egg cell stage in a manner such that the DNA is certainly present in all the germinal cells and somatic cells of the target mammal.
  • the fact that the exogenous DNA of the present invention is present in the germinal cells of the animal prepared by DNA transfer means that all offspring of the prepared animal will maintain the exogenous DNA of the present invention in all of the germinal cells and somatic cells thereof.
  • the offspring of the animal that inherits the exogenous DNA of the present invention also have the exogenous DNA of the present invention in all of the germinal cells and somatic cells thereof.
  • the non-human mammal in which the normal exogenous DNA of the present invention has been transferred can be passaged as the DNA-bearing animal under ordinary rearing environment, by confirming that the exogenous DNA is stably retained by crossing.
  • the DNA is retained to be excess in all of the germinal and somatic cells.
  • the fact that the exogenous DNA of the present invention is excessively present in the germinal cells of the prepared animal after transfer means that the DNA of the present invention is excessively present in all of the germinal cells and somatic cells thereof.
  • the offspring of the animal that inherits the exogenous DNA of the present invention have excessively the DNA of the present invention in all of the germinal cells and somatic cells thereof.
  • the normal DNA of the present invention has expressed at a high level, and may eventually develop hyperfunction symptoms of GPR39 by accelerating the function of endogenous normal DNA. Therefore, the animal can be utilized as a pathologic model animal for such a disease. For example, using the normal DNA transgenic animal of the present invention, it is possible to elucidate the mechanism of hyperfunction symptoms of GPR39 and the pathological mechanism of the disease associated with GPR39 and to investigate how to treat these diseases.
  • a mammal transferred with the exogenous normal DNA of the present invention exhibits symptoms of increasing GPR39, the animal is usable for screening of a drug for the treatment of diseases associated with GPR39.
  • a non-human mammal having the exogenous abnormal DNA of the present invention can be passaged under normal breeding conditions as the DNA-bearing animal by confirming stable retention of the exogenous DNA via crossing.
  • the exogenous DNA of interest can be utilized as a starting material by inserting the DNA into the plasmid described above.
  • the DNA construct with a promoter can be prepared by conventional DNA engineering techniques. The transfer of the abnormal DNA of the present invention at the fertilized egg cell stage is preserved to be present in all of the germinal and somatic cells of the target mammal.
  • the fact that the abnormal DNA of the present invention is present in the germinal cells of the animal after DNA transfer means that all of the offspring of the prepared animal have the abnormal DNA of the present invention in all of the germinal and somatic cells.
  • Such an offspring that passaged the exogenous DNA of the present invention will have the abnormal DNA of the present invention in all of the germinal and somatic cells.
  • a homozygous animal having the introduced DNA on both of homologous chromosomes can be acquired, and by crossing these male and female animals, all the offspring can be bred to retain the DNA.
  • the abnormal DNA of the present invention has expressed to a high level, and may eventually develop the function inactive type inadaptability to GPR39 by inhibiting the functions of endogenous normal DNA. Therefore, the animal can be utilized as a pathologic model animal for such a disease. For example, using the abnormal DNA transgenic animal of the present invention, it is possible to elucidate the mechanism of the function inactive type inadaptability to GPR39 and the pathological mechanism of the disease and to investigate how to treat the disease.
  • the transgenic animal of the present invention expressing the abnormal DNA of the present invention at a high level is expected to serve as an experimental model to elucidate the mechanism of the functional inhibition (dominant negative effect) of normal GPR39 by the abnormal GPR39 in the function inactive type inadaptability to GPR39.
  • a mammal bearing the abnormal exogenous DNA of the present invention is also expected to serve in a test for screening a drug for the treatment of the function inactive type inadaptability to GPR39, since the animal exerts symptoms of increasing GPR39.
  • clinical conditions of a disease associated with GPR39 including the function inactive type inadaptability to GPR39 can be determined by using the DNA transgenic animal of the present invention. Also, pathological findings on each organ in a disease model associated with GPR39 can be obtained in more detail, leading to the development of a new method for treatment as well as the research and therapy of any secondary diseases associated with the disease.
  • DNA transgenic animal of the present invention can serve to identify cells capable of producing GPR39, and to study in association with apoptosis, differentiation or propagation or on the mechanism of signal transduction in them to inspect any abnormality therein.
  • the DNA transgenic animal can provide an effective research material for GPR39 and for investigation of its function and effect.
  • an effective and rapid method for screening can be provided by using the method for inspection and the method for quantification, etc. described above. It is also possible to investigate and develop a method for DNA therapy for the treatment of diseases associated with GPR39, using the DNA transgenic animal of the present invention or a vector capable of expressing the exogenous DNA of the present invention.
  • the present invention provides a non-human mammalian embryonic stem cell bearing the DNA of the present invention inactivated and a non-human mammal deficient in expressing the DNA of the present invention.
  • the present invention provides:
  • a reporter gene e.g., ⁇ -galactosidase gene derived from Escherichia coli
  • a method of screening a compound that promotes or inhibits (preferably inhibits) the activity of a promoter for the DNA of the present invention which comprises administering a test compound to the mammal of [7] and detecting expression of the reporter gene.
  • the non-human mammal embryonic stem cell in which the DNA of the present invention is inactivated refers to a non-human mammal embryonic stem cell that suppresses the ability of the non-human mammal to express the DNA by artificially mutating the DNA of the present invention, or the DNA has no substantial ability to express GPR39 (hereinafter sometimes referred to as the knockout DNA of the present invention) by substantially inactivating the activities of GPR39 encoded by the DNA (hereinafter merely referred to as ES cell).
  • the knockout DNA of the present invention may be prepared, for example, by shifting the reading frame of a codon or by disrupting the function of a promoter or exon.
  • the non-human mammal embryonic stem cell in which the DNA of the present invention is inactivated (hereinafter merely referred to as the ES cell with the DNA of the present invention inactivated or the knockout ES cell of the present invention) can be obtained by, for example, isolating the DNA of the present invention that the desired non-human mammal possesses, inserting a DNA fragment having a DNA sequence constructed by inserting a drug resistant gene such as a neomycin resistant gene or a hygromycin resistant gene, or a reporter gene such as lacZ ( ⁇ -galactosidase gene) or cat (chloramphenicol acetyltransferase gene), etc.
  • a drug resistant gene such as a neomycin resistant gene or a hygromycin resistant gene
  • a reporter gene such as lacZ ( ⁇ -galactosidase gene) or cat (chloramphenicol acetyltransferase gene
  • a targeting vector e.g., a DNA sequence that terminates gene transcription (e.g., polyA additional signal, etc.) in the intron between exons, thus inhibiting the synthesis of complete messenger RNA and eventually destroying the gene (hereinafter simply referred to as a targeting vector).
  • the thus-obtained ES cells to the southern hybridization analysis with a DNA sequence on or near the DNA of the present invention as a probe, or to PCR analysis with a DNA sequence on the targeting vector and another DNA sequence near the DNA of the present invention which is not included in the targeting vector as primers, to select the knockout ES cell of the present invention.
  • the parent ES cells to inactivate the DNA of the present invention by homologous recombination, etc. may be of a strain already established as described above, or may originally be established in accordance with a modification of the known method by Evans and Kaufman described above.
  • mouse ES cells currently it is common practice to use ES cells of the 129 strain.
  • the C57BL/6 mouse or the BDF 1 mouse F 1 hybrid between C57BL/6 and DBA/2
  • the low ovum availability per C57BL/6 in the C57BL/6 mouse has been improved by crossing with DBA/2, may be preferably used, instead of obtaining a pure line of ES cells with the clear immunological genetic background and for other purposes.
  • the BDF 1 mouse is advantageous in that, when a pathologic model mouse is generated using ES cells obtained therefrom, the genetic background can be changed to that of the C57BL/6 mouse by back-crossing with the C57BL/6 mouse, since its background is of the C57BL/6 mouse, as well as being advantageous in that ovum availability per animal is high and ova are robust.
  • blastocytes at 3.5 days after fertilization are commonly used.
  • embryos are preferably collected at the 8-cell stage, after culturing until the blastocyte stage, the embryos are used to efficiently obtain a large number of early stage embryos.
  • ES cells used may be of either sex
  • male ES cells are generally more convenient for generation of a germ cell line chimera. It is also desirable that sexes are identified as soon as possible to save painstaking culture time.
  • Methods for sex identification of the ES cell include the method in which a gene in the sex-determining region on the Y-chromosome is amplified by the PCR process and detected.
  • this method is used, one colony of ES cells (about 50 cells) is sufficient for sex-determination analysis, though which convention karyotype analysis required about 10 6 cells; therefore, the first selection of ES cells at the early stage of culture can be based on sex identification, and male cells can be selected early, which saves a significant amount of time at the early stage of culture.
  • the embryonic stem cell line shows a very high growth potential, it must be subcultured with great care, since it tends to lose its ontogenic capability.
  • the embryonic stem cell line is cultured at about 37° C. in a carbon dioxide incubator (preferably 5% carbon dioxide and 95% air, or 5% oxygen, 5% carbon dioxide and 90% air) in the presence of LIF (1 to 10000 U/ml) on appropriate feeder cells such as STO fibroblasts, treated with a trypsin/EDTA solution (normally 0.001 to 0.5% trypsin/0.1 to about 5 mM EDTA, preferably about 0.1% trypsin/1 mM EDTA) at the time of passage to obtain separate single cells, which are then plated on freshly prepared feeder cells.
  • This passage is normally conducted every 1 to 3 days; it is desirable that cells be observed at the passage and cells found to be morphologically abnormal in culture, if any, be abandoned.
  • ES cells are allowed to reach a high density in mono-layers or to form cell aggregates in suspension under appropriate conditions, it is possible to differentiate the ES cells to various cell types, for example, pariental and visceral muscles, cardiac muscle or the like [M. J. Evans and M. H. Kaufman, Nature, 292. 154, 1981; G. R. Martin, Proc. Natl. Acad. Sci. U.S.A., 78, 7634, 1981; T. C. Doetschman et al., Journal of Embryology Experimental Morphology, 87, 27, 1985].
  • the cells deficient in expression of the DNA of the present invention which are obtained from the differentiated ES cells of the present invention, are useful for studying GPR39 in vitro or GPR39 cytologically.
  • the non-human mammal deficient in expressing the DNA of the present invention can be distinguished from normal animal by assaying the amount of mRNA in the animal according to a publicly known method and comparing the expression level indirectly.
  • the DNA of the present invention can be made knockout by transferring a targeting vector, prepared as described above, to mouse embryonic stem cells or mouse oocytes, and conducting homologous recombination in which a targeting vector DNA sequence, wherein the DNA of the present invention is inactivated by the transfer, is replaced with the DNA of the present invention on a chromosome of a mouse embryonic stem cell or mouse oocytes.
  • the knockout cells with the disrupted DNA of the present invention can be identified by the southern hybridization analysis using as a probe a DNA fragment on or near the DNA of the present invention, or by the PCR analysis using as primers a DNA sequence on the targeting vector and another DNA sequence at the proximal region of other than the DNA of the present invention derived from mouse used in the targeting vector.
  • a cell line wherein the DNA of the present invention is inactivated by homologous recombination is cloned; the resulting clones are injected to, e.g., a non-human mammalian embryo or blastocyst, at an appropriate stage such as the 8-cell stage.
  • the resulting chimeric embryos are transplanted to the uterus of the pseudopregnant non-human mammal.
  • the resulting animal is a chimeric animal constructed with both cells having the normal locus of the DNA of the present invention and those having an artificially mutated locus of the DNA of the present invention.
  • an individual which entire tissue is composed of cells having a mutated locus of the DNA of the present invention can be selected from a series of offspring obtained by crossing between such a chimeric animal and a normal animal, e.g., by coat color identification, etc.
  • the individuals thus obtained are normally deficient in heterozygous expression of GPR39.
  • the individuals deficient in homozygous expression of GPR39 can be obtained from offspring of the intercross between those deficient in heterozygous expression of GPR39.
  • a DNA solution may be injected, e.g., into the prenucleus by microinjection thereby to obtain a transgenic non-human mammal having a targeting vector introduced in its chromosome. From such transgenic non-human mammals, those having a mutation at the locus of the DNA of the present invention can be obtained by selection based on homologous recombination.
  • the individuals in which the DNA of the present invention is knocked out permit passage rearing under ordinary rearing conditions, after the individuals obtained by their crossing have proven to have been knockout.
  • the genital system may be obtained and retained by conventional methods. That is, by crossing male and female animals each having the inactivated DNA, homozygous animals having the inactivated DNA in both loci can be obtained.
  • the homozygotes thus obtained may be reared so that one normal animal and two or more homozygotes are produced from a mother animal to efficiently obtain such homozygotes.
  • homozygotes and heterozygotes having the inactivated DNA are proliferated and passaged.
  • the non-human mammalian embryonic stem cell in which the DNA of the present invention is inactivated, is very useful for preparing a non-human mammal deficient in expression of the DNA of the present invention.
  • non-human mammal deficient in expression of the DNA of the present invention lacks various biological activities induced by GPR39, such an animal can be used as an animal model of diseases suspected of inactivated biological activities of GPR39 and hence, is useful in the etiological studies to investigate the causes for and therapy for these diseases.
  • the non-human mammal deficient in expression of the DNA of the present invention can be employed for screening a compound or its salt having a therapeutic/preventive effect on diseases caused by deficiency, damages, etc. of the DNA of the present invention (e.g., metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs;
  • the present invention provides a method of screening a compound or its salt having a therapeutic/preventive effect on diseases caused by deficiency, damages, etc. of the DNA of the present invention, which comprises administering a test compound or test element to a non-human mammal deficient in expression of the DNA of the present invention and, observing and measuring a change occurred in the animal.
  • test compound examples include peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, blood plasma, etc. These compounds may be novel compounds or publicly known compounds.
  • salts with physiologically acceptable acids e.g., inorganic acids, etc.
  • bases e.g., organic acids, etc.
  • physiologically acceptable acid addition salts examples include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
  • organic acids e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic
  • test elements for example, the elements described in, e.g., the Periodic Table, are used. Among them, metal elements are preferred.
  • the non-human mammal deficient in expression of the DNA of the present invention is treated with a test compound or test element, comparison is made with an intact animal for control and a change in each organ, tissue, disease conditions, etc. of the animal is used as an indicator to assess the therapeutic/preventive effects of the test compound or test element.
  • test compound or test element for example, oral administration, intravenous injection, etc. are applied, and the treatment can be appropriately chosen depending on conditions of the test animal, property of the test compound or test element, etc. Furthermore, a dose of the test compound or test element to be administered can be appropriately chosen depending on the administration methods, properties of the test compound, etc.
  • test compound or test element When a test compound or test element is administered to a test animal in the screening method and the diseases described above of the test animal are cured by at least about 10%, preferably at least 30%, more preferably at least about 50%, the test compound can be selected to be a compound or its salt having a therapeutic/preventive effect on the diseases described above.
  • the compound or its salt, which is obtained using the above screening method is a compound selected from the test compounds described above and can be used as drugs, for example, a safe and low toxic agent for treating/preventing diseases caused by deficiencies, damages, etc. of GPR39 (e.g., metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs
  • salts of the compound obtained by the screening method salts with physiologically acceptable acids (e.g., inorganic acids, organic acids, etc.) or bases (e.g., alkali metal salts, etc.) may be used and preferably used are physiologically acceptable acid addition salts.
  • physiologically acceptable acids e.g., inorganic acids, organic acids, etc.
  • bases e.g., alkali metal salts, etc.
  • salts examples include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
  • organic acids e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.
  • the pharmaceutical comprising the compound or its salt obtained by the screening method can be manufactured in the same manner as the aforesaid pharmaceuticals comprising the compound that changes the binding property or signal transduction of GPR39 to the metal element
  • the pharmaceutical preparation thus obtained is safe and low toxic, it can be administered to human or mammal (e.g., rat, mouse, guinea pig, rabbit, sheep, swine, bovine, horse, cat, dog, monkey, etc.).
  • human or mammal e.g., rat, mouse, guinea pig, rabbit, sheep, swine, bovine, horse, cat, dog, monkey, etc.
  • the dose of the compound or its salt may vary depending upon target disease, subject to be administered, route of administration, etc.
  • the compound or its salt is administered to the patient (as 60 kg body weight) with, e.g., cancer generally in a daily dose of about 0.1 to about 100 mg, preferably about 1.0 to about 50 mg and, more preferably about 1.0 to about 20 mg.
  • a single dose of the compound or its salt may vary depending upon target subject, target disease, etc.
  • the compound or its salt When the compound or its salt is administered to the patient (as 60 kg body weight) with, e.g., cancer in the form of an injectable preparation, the compound or its salt is administered intravenously in a daily dose of about 0.01 to about 30 mg, preferably about 0.1 to about 20 mg, and more preferably about 0.1 to about 10 mg.
  • the corresponding dose as converted per 60 kg weight can be administered.
  • the present invention provides a method of screening a compound or its salts that promote or inhibit the activity of a promoter for the DNA of the present invention, which comprises administering a test compound to a non-human mammal deficient in expression of the DNA of the present invention and detecting the expression of the reporter gene.
  • an animal in which the DNA of the present invention is inactivated by introducing a reporter gene and the reporter gene is expressed under control of a promoter for the DNA of the present invention is used as the non-human mammal deficient in expression of the DNA of the present invention, which is selected from the aforesaid non-human mammals deficient in expression of the DNA of the present invention.
  • test compound applies to the compounds used for the screening.
  • the genes as described above may be used.
  • ⁇ -galactosidase lacZ
  • soluble alkaline phosphatase gene luciferase gene and the like, are suitable for use.
  • the reporter gene is present under control of a promoter for the DNA of the present invention in the non-human mammal deficient in expression of the DNA of the present invention wherein the DNA of the present invention is substituted with the reporter gene, the activity of the promoter can be detected by tracing the expression of a substance encoded by the reporter gene.
  • ⁇ -galactosidase gene lacZ
  • ⁇ -galactosidase is expressed in a tissue where GPR39 should originally be expressed, instead of GPR39.
  • a reagent e.g., 5-bromo-4-chloro-3-indolyl- ⁇ -galactopyranoside (X-gal) which is substrate for ⁇ -galactosidase.
  • a mouse deficient in GPR39, or its tissue section is fixed with glutaraldehyde, etc.
  • glutaraldehyde etc.
  • the system After washing with phosphate buffered saline (PBS), the system is reacted with a staining solution containing X-gal at room temperature or about 37° C. for approximately 30 minutes to an hour.
  • a staining solution containing X-gal at room temperature or about 37° C. for approximately 30 minutes to an hour.
  • the ⁇ -galactosidase reaction is terminated by washing the tissue preparation with 1 mM EDTA/PBS solution, the color formed is observed.
  • mRNA encoding lacZ may be detected in a conventional manner.
  • the compound or its salt obtained by using the screening method described above is a compound or its salt that is selected from the test compounds described above and that promotes or inhibits the activity of a promoter for the DNA of the present invention.
  • salts with physiologically acceptable acids e.g., inorganic acids, etc.
  • bases e.g., organic acids, etc.
  • physiologically acceptable acid addition salts examples include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.) and the like.
  • inorganic acids e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
  • organic acids e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic
  • the compound or its salt that promotes the activity of a promoter for the DNA of the present invention can promote the expression of GPR39 to promote the function of GPR39 and is thus useful as a pharmaceutical such as a prophylactic/therapeutic agent for, e.g., diseases associated with the dysfunction of GPR39, or as an agent for promoting the secretion of cytokines (e.g., IL-8), etc.
  • a prophylactic/therapeutic agent for, e.g., diseases associated with the dysfunction of GPR39, or as an agent for promoting the secretion of cytokines (e.g., IL-8), etc.
  • the compound or its salt that inhibits the activity of a promoter for the DNA of the present invention can inhibit the expression of GPR39 to inhibit the function of GPR39 and is thus useful as a pharmaceutical such as a prophylactic/therapeutic agent for, e.g., diseases caused by the excessive function of GPR39, or as an agent for suppressing the secretion of cytokines (e.g., IL-8), etc.
  • a prophylactic/therapeutic agent for, e.g., diseases caused by the excessive function of GPR39, or as an agent for suppressing the secretion of cytokines (e.g., IL-8), etc.
  • the diseases associated with the dysfunction of GPR39 include metal deficiency symptoms such as growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc.
  • the diseases caused by the excessive function of GPR39 include, for example, excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria including interstitial cystitis, prostatic hyperplasia induced-pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms, various disorders caused by urinary calculus, etc., or inflammatory diseases (e.g., diabetic complications such as neuropathy, large vascular disorders, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases (e.g., asthma, atopic dermatitis or chronic obstructive pulmonary disease (COPD)), etc.
  • excess metal-induced symptoms such as renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive
  • the pharmaceutical comprising the compound or its salt which is obtained by the screening method above, can be manufactured in a manner similar to the method for manufacturing the pharmaceutical comprising the compound or its salt that changes the binding property of GPR39 or its salt to the metal element described above.
  • the pharmaceutical preparation thus obtained is safe and low toxic, it can be administered to, for example, human or mammal (e.g., rat, mouse, guinea pig, rabbit, sheep, swine, bovine, horse, cat, dog, monkey, etc.).
  • human or mammal e.g., rat, mouse, guinea pig, rabbit, sheep, swine, bovine, horse, cat, dog, monkey, etc.
  • the dose of the compound or its salt may vary depending upon target disease, subject to be administered, route of administration, etc.
  • the compound or its salt that promotes the activity of a promoter for the DNA of the present invention is orally administered
  • the compound or its salt is generally administered to the patient (as 60 kg body weight) with, e.g., cancer in a daily dose of about 0.1 to about 100 mg, preferably about 1.0 to about 50 mg and, more preferably about 1.0 to about 20 mg.
  • a single dose of the compound or its salt may vary depending upon target subject, target disease, etc.
  • the compound or its salt that promotes the activity of a promoter for the DNA of the present invention is administered to the patient (as 60 kg body weight) with, e.g., cancer in the form of an injectable preparation
  • the compound or its salt is advantageously administered intravenously in a daily dose of about 0.01 to about 30 mg, preferably about 0.1 to about 20 mg, and more preferably about 0.1 to about 10 mg.
  • the corresponding dose as converted per 60 kg weight can be administered.
  • the non-human mammal deficient in expression of the DNA of the present invention is extremely useful for screening the compound or its salt that promotes or inhibits the activity of a promoter for the DNA of the present invention and can greatly contribute to elucidation of causes for various diseases suspected of deficiency in expression of the DNA of the present invention and for the development of preventive/therapeutic drugs for these diseases.
  • a so-called transgenic animal can be prepared by using a DNA containing the promoter region of GPR39, ligating genes encoding various proteins at the downstream and injecting the same into oocyte of an animal. It is thus possible to synthesize GPR39 therein specifically and study its activity in vivo.
  • an appropriate reporter gene is ligated to the promoter site described above and a cell line that expresses the gene is established, the resulting system can be utilized as the search system for a low molecular compound having the action of specifically promoting or inhibiting the in vivo productivity of GPR39 itself.
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • mRNA messenger ribonucleic acid
  • EDTA ethylenediaminetetraacetic acid
  • Trp tryptophan
  • Trt trityl
  • sequence identification numbers in the sequence listing of the specification indicates the following sequence, respectively.
  • GFP Green Fluorescent Protein
  • Agonists for GPR39 were surveyed by the method described below and as a result, it was found that particular metal elements were agonists for GPR39.
  • the human GPR39-GFP expression vector-transfected CHO cell line produced in EXAMPLE 1 was diluted in 3 ⁇ 10 4 cells/100 ⁇ l. The dilution was dispensed onto a Black walled 96-well plate (Costar) in 100 ⁇ l each per well, followed by incubation overnight in a CO 2 incubator. Changes in intracellular calcium levels were determined by the following method using FLIPR (Molecular Device). In 21 ⁇ l of DMSO (DOJIN), 50 ⁇ g of Fluo-3AM (DOJIN) was dissolved and an equal volume of 20% Pluronic acid (Molecular Probes) was added to the solution.
  • DMSO DOJIN
  • Pluronic acid Pluronic acid
  • the resulting mixture was added to 10.6 ml of assay buffer [prepared by adding 20 ml of 1M HEPES (pH 7.4) (DOJIN) to HBSS (Invitrogen Corp.) and further adding to the solution 10 ml of a solution mixture, which mixture was prepared by dissolving 710 mg of Probenecid (Sigma) in 5 ml of 1N NaOH and then adding thereto 5 ml of the HBSS/HEPES solution above] supplemented with 105 ⁇ l of fetal calf serum to prepare a fluorescent dye solution. The medium in the cell plate was removed.
  • assay buffer prepared by adding 20 ml of 1M HEPES (pH 7.4) (DOJIN) to HBSS (Invitrogen Corp.) and further adding to the solution 10 ml of a solution mixture, which mixture was prepared by dissolving 710 mg of Probenecid (Sigma) in 5 ml of 1N NaOH and then adding thereto 5 ml of the HBSS/HEPE
  • the fluorescent dye solution was dispensed in 100 ⁇ l each/well and the cells were incubated in a CO 2 incubator for an hour so that the fluorescent dye was taken up into the cells.
  • the cells after the incubation were washed with the assay buffer described above and set on FLIPR.
  • Compounds of metal elements to be added to the cells were diluted to the respective concentration with the assay buffer.
  • the dilutions were dispensed onto plates for ligands and set on FLIPR. Following the pre-treatment above, changes in intracellular calcium levels after addition of metal elements were determined by FLIPR to study agonist activities.
  • the expression level of mRNA was assayed on ABI PRISM 7900HT SequenceDetector (Applied Biosystems, Inc.). Primers [5′-TGTGACATTGGCCGTATGCT-3′ (SEQ ID NO: 3) and 5′-CAGTCGTGCTTGGGTTTGG-3′ (SEQ ID NO: 4)] and probe [5′-TGCCCAACCAGATTCGGAGGATCA-3′ (SEQ ID NO: 5)] used for quantification of the expression level were designed based on the base sequence of human GPR39 (SEQ ID NO: 2) using software PrimerExpress (Applied Biosystems, Inc.) exclusively used for ABI PRISM SequenceDetector.
  • a reaction solution for ABI PRISM 7900HT SequenceDetector was prepared by mixing 7.5 ⁇ l of TaqMan Universal PCR Master Mix (Applied Biosystems, Inc.), 0.9 ⁇ M of each primer, 0.25 ⁇ M of the probe and the cDNA solution. Distilled water was added to the mixture to make the volume 15 ⁇ l. The reaction was carried out at 50° C. for 2 minutes and 95° C. for 10 minutes and then repeating 40 times the cycle of 96° C. for 15 seconds and 60° C. for 1 minute.
  • the expression of mRNA in various human tissues and cells is shown in FIG. 5 through FIG. 7 .
  • the mRNA was highly expressed in central nervous tissues, hypophysis, kidney, gastrointestinal tract tissues, fetal brain, primary cultured cells from the vascular system, primary cultured cells from the renal system, or colon cancer cell lines.
  • the cDNAs of human GPR39, rat GPR39 and mouse GPR39 were acquired from cDNAs including the intestinal tract by RT-PCR, based on known sequences of AF034633.1 (human), XM — 222578 (rat), AK016817 and AK082941.1 (mouse), respectively.
  • the resulting DNA fragments were inserted into expression vector pAKKO-111H (the same plasmid vector as pAKKO-1.11H described in Biochem. Biophys. Acta, Hinuma, S. et al., 1219, 251-259, 1994) for animal cells.
  • pAKKO-111H the same plasmid vector as pAKKO-1.11H described in Biochem. Biophys. Acta, Hinuma, S. et al., 1219, 251-259, 1994
  • the GPR39-expressing CHO cells were acquired by the method per se known.
  • Activation of the intracellular signal transduction system by ligands using a Cytosensor was determined in terms of the pH changes by metabolism of cells as an indicator.
  • the capsule of Cytosensor capsule kit (Molecular Device) was placed on a 12-well plate (Costar) and 1 ml of the cell suspension was charged therein. After covering with the lid, the cells were incubated at 37° C. in an incubator until next day. On the day when the assay was conducted, Cytosensor was activated as instructed by the protocol.
  • RPMI1640 medium pH 7.4 (Invitrogen Corp.) (Invitrogen Corp.) for Cytosensor was prepared and equilibrated.
  • the spacer was then placed in the capsule where the cells prepared on the previous day were seeded, and the capsule was set on Cytosensor. After equilibration with the medium, a sample was added to the cells by switching the flow path and pH changes were determined.
  • the agonist activity of metal ions was detected using FLIPR in terms of the intracellular calcium-increasing reaction as an indicator.
  • the CHO cell line used, wherein rat GPR39 was stably expressed was cultured in HAM's ⁇ MEM (Invitrogen Corp.) containing 10% calf fetal serum (Invitrogen Corp.).
  • the human GPR39-expressing CHO cell line was cultured in a culture flask to reach a confluent state. After washing with PBS, the cells were scraped off using trypsin and centrifuged for recovery.
  • the cells were then suspended in medium and the suspension was adjusted to 3 ⁇ 10 5 cells/ml. Then, the suspension was dispensed onto a black walled 96-well plate (Costar) in 100 ⁇ l each per well, followed by incubation overnight in a CO 2 incubator.
  • a black walled 96-well plate (Costar) in 100 ⁇ l each per well, followed by incubation overnight in a CO 2 incubator.
  • a solution was prepared by adding 20 ml of 1M HEPES (pH 7.4) (DOJIN) to 1000 ml of HBSS (Invitrogen Corp.) (hereinafter HBSS/HEPES solution), to which solution was added 10 ml of a solution mixture obtained by dissolving 710 mg of Probenecid (Sigma) in 5 ml of 1N NaOH and further adding 5 ml of HBSS/HEPES solution thereto. The resulting solution was used as the assay buffer. Next, 50 ⁇ g of Fluo-3AM was dissolved in 21 ⁇ l of DMSO (DOJIN) and an equal volume of 20% Pluronic acid (Molecular Probes) was added to and mixed with the solution.
  • the mixture was then added to 10.6 ml of the assay buffer supplemented with 105 ⁇ l of fetal calf serum to prepare a fluorescent dye solution.
  • the medium for the CHO cells where human GPR39 was stably expressed was removed.
  • the fluorescent dye solution was dispensed in 100 ⁇ l each/well and the cells were incubated in a CO 2 incubator for an hour so that the fluorescent dye was taken up into the cells.
  • the cells after the incubation was washed with the assay buffer described above and set on FLIPR.
  • a test sample to be added to the CHO cells where rat GPR39 was stably expressed was prepared using the assay buffer and set on FLIPR at the same time.
  • the agonist activity of metal ions was detected on FLIPR in accordance with the procedures described in EXAMPLE 5, in terms of the intracellular calcium-increasing reaction as an indicator.
  • the results indicate that, when cobalt chloride (CoCl 2 ), nickel chloride (NiCl 2 ), copper chloride (CuCl 2 ), zinc chloride (ZnCl 2 ) or cadmium chloride (CdCl 2 ) was added, the intracellular calcium levels of CHO/mGPR39 was dose-dependently increased and the agonist activity for GPR39 was detected ( FIG. 14 through FIG. 18 ).
  • Isogen Natural Gene Co., Ltd.
  • cDNA was synthesized from 1 ⁇ of the total RNA obtained, according to the manual.
  • the cDNA synthesized was made a solution of 25 ng/ ⁇ l when calculated as total RNA and the solution was used as a template for the following RT-PCR.
  • Sequence Detection System Prism 7900 (PE Biosystems) was used; as primers for amplification and detection, 5′-CCCATGGAGTTCTACAGCATCAT-3′ (SEQ ID NO: 10) and 5′-TGTGGAGCTTGCAGGACAGA-3′ (SEQ ID NO: 11) were used and 5′-(Fam)-TGGAACCCCCTGACCACACCCA-(Tamra)-3′ (SEQ ID NO: 12) as a TaqMan probe.
  • a solution for RT-PCR was prepared by adding 0.135 ⁇ l each of the primer solutions each adjusted to 100 ⁇ M, 0.75 ⁇ l of the TaqMan probe adjusted to 5 ⁇ M and 1 ⁇ l of the cDNA solution prepared above to 7.5 ⁇ l of TaqMan Universal PCR Master Mix (PE Biosystems) and then adding distilled water to make the whole volume of the reaction solution 15 ⁇ l.
  • PCR was carried out, after keeping at 50° C. for 2 minutes and 95° C. for 10 minutes, by repeating 40 times the cycle of 95° C. for 15 seconds and 60° C. for 1 minute.
  • the expression levels of GPR39 mRNA in various rat tissues obtained were calculated as the number of copies per 25 ng of total RNA ( FIG. 19 ).
  • GPR39 antisense and sense probes were prepared by the following procedures. First, rat GPR39 cDNA was inserted into plasmid vector pCRII TOPO (Invitrogen Corp.) by the method per se known. This cDNA was amplified by PCR using M13 primer (Invitrogen Corp.)/Advantage 2 PCR kit (Clontech Corp.), denatured and then purified by ethanol precipitation. The cDNA was subjected to in vitro transcription (40 ⁇ l scale) by SP6 or T7 using DIG RNA Labeling KIT (SP6/T7) (Roche). After purification by ethanol precipitation, the cDNA was dissolved in distilled water to make the volume 100 ⁇ l. Based on the inserted direction of cDNA, the DIG-labeled riboprobe produced by SP6 and the DIG-labeled riboprobe produced by T7 were identified to be an antisense probe and a sense probe, respectively.
  • the antisense probe or sense probe was diluted to 200-fold with a hybridization buffer (50% formaldehyde, 10 mM Tris-HCl, pH 7.5, 1 ⁇ Denhardt's solution, 200 ⁇ g/ml tRNA, 10% dextran sulfate, 600 mM NaCl, 0.25% SDS, 1 mM EDTA), denatured at 85° C. for 10 minutes, and then added to the slice, followed by reacting at 50° C. for at least 12 hours. Subsequently, the following procedures were carried out to wash the probe hybridized non-specifically.
  • a hybridization buffer 50% formaldehyde, 10 mM Tris-HCl, pH 7.5, 1 ⁇ Denhardt's solution, 200 ⁇ g/ml tRNA, 10% dextran sulfate, 600 mM NaCl, 0.25% SDS, 1 mM EDTA
  • DIG-1 containing 1.5% Blocking reagent (Roche), and DIG-1 (1:1000) containing anti-DIG fab-fragment antibody conjugated with alkaline phosphatase (Roche) was reacted at room temperature for an hour.
  • DIG-3 100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 50 mM MgCl 2
  • DIG-3 100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 50 mM MgCl 2
  • BCIP dimethylformamide containing 0.18 mg/ml 5-bromo-4-chloro-3-indolyl-phosphate
  • NBT 4-nitroblue tetrazolium
  • polyvinyl alcohol in amounts of 0.35 ml, 0.45 ml and 3%, respectively, based on 10 ml of DIG-3.
  • the cell lines used were purchased from Dainippon Pharmaceutical and incubation procedures were performed according to the protocol attached.
  • 5637 (derived from human) was incubated in RPMI 1640 (Invitrogen Corp.) supplemented with 10% FCS to reach a pre-confluent state.
  • HT-1197 (derived from human) and HT-1376 (derived from human) were incubated in MINIMUM ESSENTIAL MEDIUM (WITH EARLE'S SALTS, WITH L-GLUTAMINE) supplemented with 10% FCS and MEM NON-ESSENTIAL AMINO ACIDS to reach a pre-confluent state.
  • MINIMUM ESSENTIAL MEDIUM WITH EARLE'S SALTS, WITH L-GLUTAMINE
  • UM-UC-3 (derived from human) and NBT-II (derived from rat) were incubated in MINIMUM ESSENTIAL MEDIUM (WITH EARLE'S SALTS, WITH L-GLUTAMINE) supplemented with 10% FCS, 1% MEM NON-ESSENTIAL AMINO ACIDS and 1 mM Sodium pyruvate to reach a pre-confluent state.
  • T24 (derived from human) and MBT-2 (derived from mouse) were incubated in MINIMUM ESSENTIAL MEDIUM (WITH EARLE'S SALTS, WITH L-GLUTAMINE) supplemented with 10% FCS to reach a pre-confluent state.
  • RNA and synthesis of cDNA were performed according to the manual of ISOGEN (Nippon Gene). The total RNA was thus extracted and purified. From 1 ⁇ g of the extracted RNA, first strand cDNA was synthesized using random in accordance with the manual for SuperScript II (Invitrogen Corp.), precipitated in ethanol and dissolved in 10 ⁇ l of TE.
  • TaqMan quantification was performed on the cell line-derived cDNA (corresponding to 25 ng RNA), using amplification reagent TaqMan (trademark), Universal PCR Master Mix (Applied Biosystems JAPAN Ltd.) and TaqMan (trademark) primer-probe set for GPR39 detection.
  • the primer-probe set described in EXAMPLE 3 was used for human-derived samples.
  • the primer-probe set described in EXAMPLE 7 was used for rat-derived samples.
  • 5′-GTACCCACTCACAAGGGACTCAAC-3′ SEQ ID NO: 13
  • 5′-TATTGGAGTTTCCAGGTTCATCGT-3′ SEQ ID NO: 14
  • 5′-(Fam)-CAACCTCTCTCGCACCCGCCA-(Tamra)-3′ SEQ ID NO: 15
  • the reaction was carried out in 15 ⁇ l in total of the reaction solution. The final concentrations of the respective primers and probes were in accordance with the manual.
  • TaqMan (trademark) PCR was carried out on ABI PRISM (trademark) 7900HT sequence detection system (Applied Biosystems JAPAN Ltd.). The temperature cycle used was complied with the manual of TaqMan (trademark) Universal PCR Master Mix (Applied Biosystems JAPAN Ltd.).
  • Quantitative TaqMan analysis of the amplification product was performed using 7900HT SDS software (Applied Biosystems JAPAN Ltd.).
  • the calibration curve used to count the copy number was prepared from CT values in six logarithms from 10 7 copies/well to 10 2 copies/well using the cDNA fragment (human GPR39) or plasmid DNA (mouse GPR39) of known concentrations, including the full length amplification region.
  • the cell lines used were purchased from Dainippon Pharmaceutical and incubation procedures were performed according to the protocol attached. 5637 was incubated in RPMI 1640 (Invitrogen Corp.) supplemented with 10% FCS to reach a pre-confluent state. HT-1197 and HT-1376 were incubated in MINIMUM ESSENTIAL MEDIUM (WITH EARLE'S SALTS, WITH L-GLUTAMINE) supplemented with 10% FCS and MEM NON-ESSENTIAL AMINO ACIDS to reach a pre-confluent state.
  • MINIMUM ESSENTIAL MEDIUM WITH EARLE'S SALTS, WITH L-GLUTAMINE
  • UM-UC-3 and NBT-II were incubated in MINIMUM ESSENTIAL MEDIUM (WITH EARLE'S SALTS, WITH L-GLUTAMINE) supplemented with 10% FCS and MEM NON-ESSENTIAL AMINO ACIDS to reach a pre-confluent state.
  • T24 and MBT-2 were incubated in MINIMUM ESSENTIAL MEDIUM (WITH EARLE'S SALTS, WITH L-GLUTAMINE) supplemented with 10% FCS to reach a pre-confluent state.
  • Changes in intracellular calcium levels were determined on FLIPR according to the procedures described in EXAMPLE 5. The results indicate that a reaction with nickel was detected in UM-UC-3 and HT-1197.
  • UM-UC-3 was cultured in MINIMUM ESSENTIAL MEDIUM (WITH EARLE'S SALTS, WITH L-GLUTAMINE) supplemented with 110% FCS and MEM NON-ESSENTIAL AMINO ACIDS to reach a pre-confluent state. After washing with PBS, the cells were scraped off using trypsin and centrifuged for recovery. The cells were then suspended in medium and the suspension was adjusted to 1.5 ⁇ 10 5 cells/ml. Next, the suspension was dispensed in a 6-well plate (Falcon) at 5 ml each per well, followed by incubation overnight in a CO 2 incubator.
  • MINIMUM ESSENTIAL MEDIUM WITH EARLE'S SALTS, WITH L-GLUTAMINE
  • the medium for the cells prepared on the previous day was removed and the cells were washed with MINIMUM ESSENTIAL MEDIUM (WITH EARLE'S SALTS, WITH L-GLUTAMINE) supplemented with MEM NON-ESSENTIAL AMINO ACIDS. Then, 5 ml each was added to each well, followed by incubation at 37° C. in a CO 2 incubator for an hour.
  • MINIMUM ESSENTIAL MEDIUM WITH EARLE'S SALTS, WITH L-GLUTAMINE
  • mice of 9-10 weeks old were anaesthetized by intramuscular injection with 0.1 ml/100 g of a solution obtained by mixing ketamine (50 mg/mL) and xylazine (20 mg/mL) in 5:1.
  • the bladder was then exposed via a midline incision and a hole was made with a 20-G needle to insert a polyethylene tube (PE-50), which tube was sutured to the bladder with cotton thread.
  • the polyethylene tube cannulated into the bladder was cut at a length of about 1 cm, which was connected to a silicon tube (No. 00) and exposed to the dorsum through the skin.
  • the animals were housed in individual cages until they were used for the experiments.
  • Saline was infused into the bladder at the rate of 6 ml/hr and the infusion was continued for 1 or 2 hours until stable micturition was recorded.
  • protamine sulfate (10 mg/mL in PBS) was infused into the bladder for an hour (Chuang Y, et. al., 2003, Urology, 63, 664-670). Any substantial change in micturition intervals was noted by the protamine infusion when compared to those prior to the infusion. Then, saline was reinfused into the bladder and micturition was recorded at least 2 hours until protamine was completely washed off.
  • GPR39 and its ligand or an ionizable metal element such as cadmium, zinc, copper, nickel, etc. or a salt thereof By using GPR39 and its ligand or an ionizable metal element such as cadmium, zinc, copper, nickel, etc. or a salt thereof, a compound or its salt that changes the binding property of the metal element or a salt thereof to GPR39 can be efficiently screened.
  • an agonist having a more potent activity can be found by using the screening method of the present invention.
  • the agonist for GPR39 is useful as a prophylactic/therapeutic agent for metal deficiency symptoms, for example, growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, prostatic hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, swelling, wrinkles, sagging, hypothyroidism, depression, menoxenia, hypotonic bladder induced by sensory decrease of the bladder by diabetes mellitus, etc., hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs; etc., or an agent for promoting the secretion of cytokines (e.g., IL-8).
  • cytokines e.g., IL-8
  • the antagonist for GPR39 is useful as a prophylactic/therapeutic agent for excess metal-induced symptoms, for example, renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy, Wilson's disease, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria including interstitial cystitis, prostatic hyperplasia induced-pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms, excess metal-induced symptoms including various disorders caused by urinary calculus, etc; an agent for suppressing the secretion of cytokines (e.g., IL-8); or a prophylactic/therapeutic agent for inflammatory diseases (e.g., diabetic complications such as neuropathy, large vascular disorders, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia), allergic diseases (e.g., asthma, atopic dermatitis, chronic obstruct

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Threshing Machine Elements (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US10/552,014 2003-04-25 2004-04-23 Novel screening method Abandoned US20060216286A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/428,877 US7972800B2 (en) 2003-04-25 2009-04-23 Screening method for binding property or signal transduction alterations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003122464 2003-04-25
JP2003-122464 2003-04-25
PCT/JP2004/005947 WO2004097411A1 (fr) 2003-04-25 2004-04-23 Nouvelle methode de criblage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/428,877 Division US7972800B2 (en) 2003-04-25 2009-04-23 Screening method for binding property or signal transduction alterations

Publications (1)

Publication Number Publication Date
US20060216286A1 true US20060216286A1 (en) 2006-09-28

Family

ID=33410077

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/552,014 Abandoned US20060216286A1 (en) 2003-04-25 2004-04-23 Novel screening method
US12/428,877 Expired - Fee Related US7972800B2 (en) 2003-04-25 2009-04-23 Screening method for binding property or signal transduction alterations

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/428,877 Expired - Fee Related US7972800B2 (en) 2003-04-25 2009-04-23 Screening method for binding property or signal transduction alterations

Country Status (5)

Country Link
US (2) US20060216286A1 (fr)
EP (1) EP1619499B1 (fr)
AT (1) ATE494550T1 (fr)
DE (1) DE602004030899D1 (fr)
WO (1) WO2004097411A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075836A1 (en) * 2005-10-20 2009-03-19 Viamet Pharmaceuticals, Inc. Screening for modulators of metalation pathways for metalloproteins

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781175B2 (en) 2004-04-23 2010-08-24 Takeda Pharmaceutical Company Limited Method of screening compounds which alter the binding properties of GPR39, and homologs thereof, to bile acid
EP1747462A2 (fr) * 2004-04-27 2007-01-31 Galapagos N.V. Proc d s, agents, et analyses de criblage de compos s permettant d'induire une diff renciation de cellules mammaliennes non diff renci es en ost oblastes
WO2008030252A2 (fr) * 2005-10-20 2008-03-13 Viamet Pharmaceuticals, Inc. Compositions et méthodes de criblage d'apoprotéines
CN101467047A (zh) * 2006-06-08 2009-06-24 詹森药业有限公司 G蛋白偶联受体39

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004491A1 (en) * 1999-09-10 2002-01-10 Jiangchun Xu Compositions and methods for the therapy and diagnosis of ovarian cancer
US6599718B1 (en) * 1998-07-13 2003-07-29 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720146B2 (en) * 1999-09-10 2004-04-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1280937A2 (fr) 2000-04-26 2003-02-05 Millennium Pharmaceuticals, Inc. Methodes et compositions destinees au diagnostic et au traitement des maladies cardio-vasculaires et tumorigenes a l'aide de 4941
WO2002061087A2 (fr) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
CA2438030A1 (fr) 2001-02-14 2002-10-10 Protein Design Labs Methode de diagnostic de l'angiogenese, preparations et methodes d'identification par criblage de modulateurs de l'angiogenese
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
JP2003024070A (ja) * 2001-06-05 2003-01-28 Pharma Design Inc 新規なｇタンパク質共役型受容体タンパク質及びその遺伝子
JP2003047472A (ja) * 2001-08-01 2003-02-18 Takeda Chem Ind Ltd 新規ｇタンパク質共役型レセプタータンパク質およびそのｄｎａ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599718B1 (en) * 1998-07-13 2003-07-29 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
US20020004491A1 (en) * 1999-09-10 2002-01-10 Jiangchun Xu Compositions and methods for the therapy and diagnosis of ovarian cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075836A1 (en) * 2005-10-20 2009-03-19 Viamet Pharmaceuticals, Inc. Screening for modulators of metalation pathways for metalloproteins

Also Published As

Publication number Publication date
WO2004097411A1 (fr) 2004-11-11
US7972800B2 (en) 2011-07-05
US20090227037A1 (en) 2009-09-10
DE602004030899D1 (de) 2011-02-17
EP1619499A1 (fr) 2006-01-25
ATE494550T1 (de) 2011-01-15
EP1619499A4 (fr) 2008-03-05
EP1619499B1 (fr) 2011-01-05

Similar Documents

Publication Publication Date Title
US7833722B2 (en) Ligands for G protein-coupled receptor protein and use thereof
US7556926B2 (en) Methods for screening insulin-sensitizing agents
US7972800B2 (en) Screening method for binding property or signal transduction alterations
CA2592201C (fr) Neuromedine s et son utilisation
US7172876B2 (en) Method of screening therapeutic agents for nerve degeneration associated diseases
US7781175B2 (en) Method of screening compounds which alter the binding properties of GPR39, and homologs thereof, to bile acid
US20060073516A1 (en) Novel screening method
JP4542810B2 (ja) 新規スクリーニング方法
US20040248208A1 (en) Screening method
US7927821B2 (en) Methods of screening for compounds which bind G protein-coupled receptors
US7892755B2 (en) Screening method
US7517661B2 (en) Methods of screening for ligands for FPRL2
US7754856B2 (en) Human sodium-dependent bile acid transporter proteins
US20040248209A1 (en) Use of g protein-coupled receptor protein
EP1876238A1 (fr) Nouveau polypeptide et utilisation
JP2004198201A (ja) 新規スクリーニング方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ITO, YASUAKI;FUJII, RYO;KOBAYASHI, MAKOTO;AND OTHERS;REEL/FRAME:017567/0218;SIGNING DATES FROM 20050810 TO 20050830

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION